Check for updates

OPEN ACCESS

EDITED BY Swathi Kiran, Boston University, United States

REVIEWED BY Xun Luo, Kerry Rehabilitation Medicine Research Institute, China Anastasios M. Georgiou, Cyprus University of Technology, Cyprus Jessica Richardson, University of New Mexico, United States

*CORRESPONDENCE Shanli Yang ⊠ 49688400@qq.com

[†]These authors have contributed equally to this work

RECEIVED 05 December 2023 ACCEPTED 16 April 2024 PUBLISHED 01 May 2024

CITATION

Cheng J, Jiang Y, Rao T, Yang Y, Liu Y, Zhan Y and Yang S (2024) Repetitive transcranial magnetic stimulation for poststroke non-fluent aphasia: a systematic review and meta-analysis of randomized controlled trials. *Front. Neurol.* 15:1348695. doi: 10.3389/fneur.2024.1348695

COPYRIGHT

© 2024 Cheng, Jiang, Rao, Yang, Liu, Zhan and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Repetitive transcranial magnetic stimulation for post-stroke non-fluent aphasia: a systematic review and meta-analysis of randomized controlled trials

Jing Cheng^{1†}, Yijing Jiang^{2†}, Ting Rao^{2,3†}, Yihan Yang³, Yanping Liu^{2,3}, Ying Zhan³ and Shanli Yang²*

¹First School of Clinical Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China, ²Affiliated Rehabilitation Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, China, ³School of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China

Objective: To systematically evaluate the efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) on language function in patients with non-fluent aphasia post-stroke.

Methods: We selected randomized clinical trials (RCT) that involved stroke patients with non-fluent aphasia, whose intervention was rTMS vs. no therapy or other therapy. Two researchers autonomously reviewed the literature based on the specified criteria for inclusion and exclusion and completed the process of data extraction, data verification, and quality evaluation. Meta-analysis was performed using RevMan 5.4¹ and Stata MP 17², while the assessment of risk of bias was carried out utilizing the Risk of Bias version 2 tool (RoB2)³.

Results: The meta-analysis involved 47 RCTs, encompassing 2,190 patients overall. The indexes indicated that rTMS has the potential to decrease the severity of non-fluent aphasia in stroke patients, including improvement of the capability of repetition, naming, and spontaneous language. The determination of BDNF in the serum of patients was also increased. In addition, rTMS reduced the likelihood of depression in stroke patients.

Conclusion: To summarize the relevant studies, rTMS has significant effects on improving the language abilities of stroke patients suffering from non-fluent aphasia, including the abilities of repetition, naming, and spontaneous language.

KEYWORDS

stroke, non-fluent aphasia, meta-analysis, repetitive transcranial magnetic stimulation, systematic review

¹ https://revman.cochrane.org/info

² https://www.stata.com/

³ https://methods.cochrane.org/risk-bias-2

Introduction

Stroke remains a primary cause of mortality and morbidity globally (1, 2). Approximately 38% of adult stroke victims are subsequently diagnosed with aphasia (3, 4), which further worsens the prognosis for these patients. The severity of aphasia is useful in predicting the functional autonomy of patients, as well as their short-term and long-term recovery outcomes following a stroke (5, 6). Patients suffering from post-stroke aphasia (PSA) exhibit significantly elevated mortality rates and poorer functional outcomes compared to those without the condition (7). Therefore, rehabilitation therapy after a stroke places a paramount emphasis on the restoration of language function.

Non-fluent aphasia (NFA), frequently observed in individuals recovering from stroke, results from damage to areas encompassing the left inferior frontal gyrus (IFG-L), namely Broca's area, along with transcortical motor, global, and mixed transcortical aphasia (8, 9). Patients with NFA may exhibit notable impairments in language production, poor sentence repetition, poor verbal agility, and errors in sentence construction (9–11). Traditional speech and language therapies (SLTs) rarely lead to the complete restoration of linguistic functions. Therefore, it is clear that patients with NFA after stroke require more adjunctive and enhancing therapies (12).

Repetitive transcranial magnetic stimulation (rTMS) utilizes magnetic fields to elicit electrical currents within targeted areas of brain. This technique modulates cortical excitability in both the stimulated areas and distant regions by delivering consistent stimuli at extremely short intervals. This process helps restore inter-hemispheric balance and allows for precise control of stimulation parameters (frequency and location), significantly affecting the functional brain network (13). rTMS induces long-lasting neuroplastic changes and facilitates network-related brain reconstruction (14). Theta-burst stimulation (TBS), an advanced form of rTMS, is subdivided into intermittent theta-burst stimulation (iTBS) and continuous theta-burst stimulation (cTBS) (15). Different rTMS stimulation frequencies yield varied effects on cerebral cortex activity: high-frequency stimulation (\geq 5 Hz) and iTBS enhance local neuronal excitability, whereas low-frequency stimulation (\leq 1 Hz) and cTBS reduce it (16).

Martin et al. (17) first reported to support language recovery, yet conclusive findings are elusive, and influenced by various factors. An important consideration is whether SLT should be paired with rTMS. Several studies suggested that when employed as a standalone therapy, rTMS holds promise in producing language improvements in PSA (6, 18–20). On the contrary, the suggestion that rTMS could prime the brain for behavioral therapy, implying that it should be integrated with SLT, is met with challenges. Heterogeneity in SLT types and intensities among recent studies used alongside rTMS (21–24) contribute to the complexity of this argument. It is challenging to precisely define the individual contributions of rTMS and SLT and assess their collective impact on PSA rehabilitation that rTMS could offer a unique, complementary approach to treating aphasia. Current research into PSA rehabilitation has used rTMS to modulate interhemispheric interaction.

Numerous randomized controlled trials (RCTs) (25) suggest that rTMS may aid in the reconstruction and recovery of language abilities in individuals with PSA. Six systematic reviews (25–30) evaluated the impact of rTMS on PSA, with most reaching inconsistent conclusions or having loose exclusion criteria; the types of aphasia in patients were

also ambiguously defined. Georgiou et al. (31) utilized the AMSTAR 2 tool to evaluate the quality of systematic reviews of RCTs focusing on the effectiveness of rTMS in aphasia rehabilitation following stroke before July 2017 and found that the quality of these studies was generally low. Another meta-analysis (32) identified the types of NFA in stroke patients, but the included literature was outdated. Consequently, we conducted a systematic review to furnish evidence-based information regarding the application of rTMS in treating NFA following a stroke. This involved analyzing a large number of studies and more relevant outcome indices, to identify new research directions.

Methods

This systematic review adheres to the guidelines set forth by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (33). And the study protocol has been officially registered in PROSPERO (ID CRD42023434714).

Our PICO question was: in stroke patients with NFA, does rTMS, as compared to the absence of therapy or alternative treatments, reduce the severity of aphasia in patients, including naming, spontaneous language, and repetition abilities?

Search strategy

We searched nine commonly used electronic databases: PubMed, Cochrane Library, Embase, Web of Science, SinoMed, OVID, the China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and Wanfang Data for RCTs of rTMS for stroke patients with NFA. Furthermore, relevant systematic evaluations and reference lists of included studies were searched manually to ensure the comprehensiveness of included studies. Keywords were determined after preretrieval: repetitive transcranial magnetic stimulation, rTMS, TBS, stroke, cerebrovascular accident, aphasia, non-fluent aphasia, and post-stroke aphasia. The final literature search was conducted on January 8, 2024, using neither language nor publication date restrictions.

Inclusion and exclusion criteria

Inclusion criteria (1) study design: RCTs; (2) study population: individuals with NFA following a clinical diagnosis of stroke; (3) interventions: In addition to the interventions applied to the control group, the experimental group underwent rTMS. Alternatively, the experimental group received rTMS, whereas the control group received sham-rTMS. For studies encompassing more than two groups, the groups fulfilling the inclusion criteria were also included; (4) the outcome indicators ought to incorporate at least one metric of aphasia assessment, such as Western Aphasia Battery (WAB), Aphasia Battery of Chinese (ABC), China Rehabilitation Research Center Standard Aphasia Examination (CRRCAE), and Boston Naming Test (BNT).

Exclusion criteria: (1) duplicate studies or data cannot be extracted; (2) case studies, animal experimental studies, or reviews; (3) the unavailability of full text even after contacting the author via email.

10.3389/fneur.2024.1348695

Study selection and data extraction

Endnote X9 was utilized for document organization and deduplication. Two reviewers independently conducted literature screening, data extraction, and cross-verification according to predetermined inclusion and exclusion criteria. Any discrepancies between the reviewers were resolved by achieving a consensus with an unbiased third-party researcher. The process of extracting data entailed gathering details regarding the title, first author, publication year, the number of patients, diagnostic criteria, intervention and control protocols, rTMS parameters (e.g., stimulation site, frequency, intensity, and duration), outcome measures, any reported adverse events and follow-up duration.

Risk-of-bias

Risk of bias assessment for the studies included was carried out utilizing the RoB2 tool (34). Two researchers evaluated the risk of bias independently, with any discrepancies being resolved by a third researcher.

Statistical analysis

Meta-analysis was conducted utilizing Revman 5.4 software. The mean differences (MD) along with the 95% confidence interval (CI) were employed for statistical analysis, and the standardized mean difference (SMD) was used when using different measurement methods or units. Statistically significant differences were indicated by p < 0.05, and the magnitude of heterogeneity was quantified using I^2 . I^2 shows the proportion of heterogeneity in the total variation of effect size based on the Student–Newman–Keuls test, ranging from 0 to 100%. $I^2 \leq 50\%$ was deemed as an indication of low heterogeneity, employing the fixed-effects model for Meta-analysis; $I^2 > 50\%$ was considered a clear indication of significant heterogeneity, utilizing the random-effects model.

Results

Search results

The initial search returned 1,244 articles. Following the removal of duplicate articles, 607 studies were left, and 59 studies remained upon reviewing the titles and abstracts. Finally, 47 studies were included after a rigorous evaluation of the full-text articles (Supplementary Figure S1).

Characteristics of included studies

Out of the 48 studies (4, 23, 35-80), 37 studies (35-37, 39-49, 51, 52, 54-66, 68, 69, 72-74, 76, 78, 79) had reported diagnostic criteria for stroke and 35 (4, 35-39, 41-53, 55, 57-60, 62-65, 67-70, 74, 76, 77) for aphasia. In 43 studies (4, 23, 35-52, 54-65, 67-76, 78, 80), the age of the patient was reported as mean ± standard deviation, while two studies (53, 66) reported specific age information for each patient, and the age range was reported in two studies (77, 79). Except for two studies (50, 59) that failed to disclose the post-stroke time, the mean

course of disease for patients in the other 44 studies (4, 23, 35–49, 51, 52, 54–58, 60–65, 67–80) ranged from 6.9 days to 4.46 years, and two studies (53, 66) reported specific course of disease for each patient. Of the total studies, 39 studies (4, 35–43, 45–48, 51–55, 58–70, 72–74, 77–80) specifically reported that the patients were right-handed, whereas the remaining 9 studies (23, 44, 49, 50, 56, 57, 71, 75, 76) failed to furnish this information. Duration of the intervention in 45 studies (4, 23, 35, 36, 38–40, 42–46, 48–80) spanned from 2 to 4 weeks, except for 2 studies (37, 41) with an intervention duration of 30 days and one (47) with 8 weeks. Regarding the content of the intervention, five studies (49, 50, 59, 71, 80) used rTMS or sTMS alone, and the remaining studies also had aphasia treatment components including SLT, acupuncture, and electroacupuncture (EA). Patients were followed up after treatment in 15 studies (4, 39, 40, 53, 57, 66, 67, 70–74, 77, 78, 80), ranging from 30 days to 12 months.

Adverse events were mentioned in 10 studies (4, 40, 42, 45, 51, 57, 60, 61, 73, 77). Six studies (4, 40, 42, 45, 60, 73) reported headache; three (40, 45, 51) reported dizziness; adverse effects of epilepsy seizures were seen in two studies (61, 77). One study (57) documented the occurrence of adverse events such as disorientation, injuries resulting from falls, and aspiration caused by dysphagia among both control and experimental participants, the ratio of aspiration was the highest in the experimental group (3 cases), and the control group (11 cases), which revealed that the combination of rTMS and speech training could reduce the complications and improve the therapeutic efficiency.

Regarding the NFA type, 16 studies (23, 37, 41, 42, 44, 45, 47-49, 54, 56, 57, 61, 74, 78, 79) included patients with Broca aphasia. Four studies (36, 53, 63, 64) included patients with global aphasia, and 5 studies (39, 43, 72, 73, 76) reported on the number of patients with different types of aphasia. The aphasia types of patients in the three studies (43, 72, 73) were global, Broca's, and transcortical motor aphasia, and Wang's (73) study included patients with mixed transcortical aphasia. In addition to the intervention received by the control group, the experimental group in one study (48) received high-frequency TMS (HF-rTMS) on the IFG-L. One study (67) performed bilateral cerebral pulse stimulation, with HF-rTMS (> 1 Hz) stimulating the left cerebral Broca area and low-frequency TMS $(\leq 1 \text{ Hz})$ (LF-rTMS) stimulating the right Broca area; three studies (38, 46, 56) stimulated the right inferior frontal gyrus (IFG-R) with 0.5 Hz. Of the 40 studies with a frequency of 1 Hz, except for one study (53) in which the stimulation site was the right superior temporal gyrus, the stimulation site was the IFG-L. Three of these studies (32, 66, 80) further stimulated Brodmann 45 (pars triangularis) at the site of the IFG-R partition. Three studies (43, 58, 77) proceeded theta burst stimulation (TBS) on patients, one (77) conducted passive cTBS on the cerebellum in patients of the experimental group, and the other two (43, 58) conducted iTBS on the IFG-L. The critical characteristics of the included studies have been summarized in Table 1.

Methodological quality

The outcomes of the risk-of-bias assessments conducted for each included study are shown in Supplementary Figures S2A,B.

Potential publication bias across the included studies was evaluated based on Egger's tests in Stata MP 17, with a significance level set at p < 0.1 (Supplementary Table S1).

TABLE 1 Basic characteristics of the included studies.

Studies and year		nostic teria	Total patients (C/E)	Age (years)	Course of disease	Hand- edness	Interv	ention		rTMS paramet	ers	Duration	Outcome indicators	Follow up (after treatment)
	Stroke	Aphasia					С	E	FRQ (Hz)	Intensity	Stimulation sites			
Cao HY, 2023	CT/MRI	Û	90 (30/30)	C:56.97±14.25 E:57.80±11.69	C:49.43 ± 18.14 D E:54.73 ± 17.40 D	R	SLT + Eye tracking training	SLT + Eye tracking training+rTMS	1	80–120% of the MT, 1000 pulses	IFG-R	5d/w×4w	D	NR
Jiang XC, 2023	CT/MRI	3	50 (25/25)	C:63.57±9.69 E:58.86±12.81	35.04 ± 30.65 D 39.95 ± 28.84 D	R	SLT + S-rTMS	SLT+iTBS	50	80% of the rMT, 600 pulses	IFG-L	6d/w×4w	03	NR
Zhu HM, 2023	CT/MRI	0	60 (30/30)	$\begin{array}{c} \text{C:58.0} \pm 11.8 \\ \text{E:59.7} \pm 13.6 \end{array}$	C:42.5 D E:34.5 D	R	SLT	SLT + rTMS	1	80% of the rMT, 1,000 pulses	IFG-R	6d/w×3w	0	NR
Liu SJ, 2023	CT/MRI	٢	92 (46/46)	$\begin{array}{c} \text{C:50.29} \pm 9.768 \\ \text{E:53.41} \pm 10.23 \end{array}$	C:56.98±31.56 D E:53.26±29.98 D	R	SLT + drug treatment+ S-rTMS	SLT + drug treatment+rTMS	0.5	80% of the rMT	IFG-R	5d/w×4w	239®	NR
Liu SL, 2022	CT/MRI	03	70 (35/35)	C: 63.46±9.57 E: 60.94±7.80	C: 60.06 ± 22.56 D E: 56.89 ± 24.80 D	R	SLT + acupuncture treatment	SLT + acupuncture treatment+ rTMS	1	The sequence pulse is 30 times	IFG-R	$20 \min/d \times 5d/w \times 8w$	03	NR
Xu DM, 2022	CT/MRI	٢	60 (30/30)	C:63.5±2.4 E:63.6±2.5	C:5.1±1.3 M E:5.2±1.4 M	NR	SLT	SLT + rTMS	1	80% of the MT	IFG-R	5d/w×4w	00	3 M
Zheng Y, 2022	CT/MRI	0	45 (15/15)	C:53.27 ± 14.83 E:50.53 ± 13.85	C:50.20 ± 18.52 D E:52.60 ± 18.06 D	R	SLT + attention function training	SLT + attention function training+rTMS	1	80–70% of the MT, 1000 pulses	BA45	$20 \min/d \times 5d/w \times 4w$	008	NR
Zhou HY, 2021	CT/MRI	NR	106 (53/53)	C:59.87±7.64 E:61.25±8.41	C:8.91 ± 2.36 W E:9.35 ± 3.27 W	R	SLT	SLT+rTMS	1	90% of the MT	IFG-R	5d/w×4w	181	NR
Wang GX, 2021	CT/MRI	NR	26 (14/12)	$C:52.79 \pm 12.80$ $E:52.42 \pm 10.56$	C/E:3-6 M	R	SLT	SLT + rTMS	1	90% of the MT, 1200 pulses in total	IFG-R	$20 \min/d \times 5d/w \times 2w$	13	NR
Li WT, 2021	CT/MRI	0	120 (60/60)	$\begin{array}{c} \text{C:}50.88 \pm 6.09 \\ \text{E:}51.02 \pm 5.78 \end{array}$	C:8.68 ± 2.16 D E:8.57 ± 1.38 D	NR	SLT+ acupuncture	SLT + rTMS+ acupuncture	1	80% of the MT, 50 pulses per sequence, 10 sequences per day	IFG-R	20 min/d×6d/w×4w	0	NR
Zhang DH, 2021	CT/MRI	٩	30 (10/10)	$C:50 \pm 08$ E:50 ± 13	C:4.4±1.2 M E:3.9±1.0 M	R	SLT	SLT + rTMS	5	80% of the AMT,	IFG-L	5d/w×2w	PACA	NR
Zhu HM, 2021	CT/MRI	٩	30 (10/10)	C:60.4±8.3 E:61.6±14.7	C:228.5 D E:246.5 D	R	SLT + MNTS	SLT+MNTS+rTMS	1	80% of the MT, 1000 pulses	IFG-R	6d/w×3w	03	NR
Zhu HM, 2020	CT/MRI	Û	50 (16/18)	C:60.75±9.00 E:57.89±14.15	C:52.00 D E:69.00 D	R	SLT + MNS	SLT + MNS + rTMS	1	80% of the MT, 1000 pulses	IFG-R	2times/d×6d/w×3w	03	NR
Qiu LF, 2020	CT/MRI	0	60 (20/20)	$\begin{array}{c} \text{C:52.25} \pm 15.00 \\ \text{E:55.00} \pm 10.72 \end{array}$	C:1.56±1.63 M E:2.12±1.72 M	R	SLT + Schuell stimulation	SLT + Schuell stimulation+rTMS	1	80% of the MT, 1200 pulses per day	IFG-R	5d/w×4w	03(1)	NR
Qu YZ, 2020	CT/MRI	0	40 (20/20)	$C:67.80 \pm 7.32$ E:68.60 ± 7.78	C:25.80±11.77 D E:26.50±12.51 D	R	SLT	SLT + rTMS	1	100% of the rMT, 1,200 pulses	IFG-R	5d/w×2w	19	NR
Qin Q, 2020	NR	Ū	76 (38/38)	C:57.84±12.49 E:57.94±11.39	NR	NR	НВО	HBO+rTMS	1	80% of the rMT	IFG-R	$20 \min/d \times 5d/w \times 4w$	00	NR

Cheng et al.

(Continued)

TABLE 1 (C	Continued)
------------	------------

Studies and year		nostic teria	Total patients (C/E)	Age (years)	Course of disease	Hand- edness	Interv	ention		rTMS paramet	ers	Duration	Outcome indicators	Follow up (after treatment)
	Stroke	Aphasia					с	E	FRQ (Hz)	Intensity	Stimulation sites			
Chen Y, 2020	CT/MRI	3	30 (15/15)	C:61.9±10.7 E:56.6±15.1	C:10.7±4.4W E:9.5±3.3W	R	SLT + drug treatment+ S-rTMS	SLT + drug treatment+rTMS	1	100% of the rMT	IFG-R	20 min/d×5d/w×2w	312	30D
Pan LS, 2019	CT/MRI	2	44 (22/22)	C:64.41 ± 11.53 E:68.85 ± 8.97	C:45.00±21.69 D E:53.65±24.92 D	R	RT + EA	RT + EA + rTMS	5	80% of the MT	IFG-L	$12 \min/d \times 5 d/w \times 4w$	2010	NR
Qiao Y, 2019	CT/MRI	2	44 (22/20)	C: 58.64±9.99 E: 60.70±9.74	C: 57.32±16.54 D E: 53.50±19.76 D	NR	RT + EA	RT + EA + rTMS	1	20 sequences, and stimulation intensity ranging from 30 to 50%	IFG-R	$20 \min/d \times 5d/w \times 4w$	00W	NR
Zhang Y, 2019	CT/MRI	1	48 (16/16)	C: 60.7±8.7 E: 60.6±9.1	NR	R	RT + HBO	RT + HBO + rTMS	1	120 sequences,960 pulses	IFG-R	$20 \min/d \times 5d/w \times 4w$	00	NR
Wang JR, 2018	CT/MRI	2	35 (18/17)	$C:55.00 \pm 11.35$ $E:47.07 \pm 12.52$	C:40.87±21.86 D E:39.40±24.05 D	R	SLT + drug treatment	SLT + drug treatment+rTMS	1	80% of the MT	IFG-R	$20 \min/d \times 5d/w \times 4w$	0	NR
Ren CL, 2018	NR	0	14 (6/6)	Specific age information for each patient	Specific course of disease for each patient	R	SLT + S-rTMS	SLT + rTMS	1	80% of the MT	STG-R	20 min/d×5d/w×3w	0	3 and 6 M
Li ZH, 2018	CT/MRI	0	30 (13/13)	C:68.3±5.8 E:65.3±5.6	C:51.0±9.6 D E:47.5±7.4 D	R	SLT + S-rTMS	SLT + rTMS	1	80% of the MT	IFG-R	$20 \min/d \times 5d/w \times 3w$	①+QEEG	NR
Chang L, 2018	MRI	0	126 (63/63)	C:66.4±15.8 E:67.3±19.9	C:7.3±3.5 D E:6.9±3.1 D	R	SLT	SLT + rTMS	1	80% of the MT	IFG-R	ST 30 min/d×15d rTMS 20 min/d×15d	0	NR
Wu G, 2017	CT/MRI	NR	180 (90/90)	56.91±9.70	C/E:3.47±1.16 D	NR	SLT	SLT + rTMS	0.5	80% of the MT	IFG-R	5d/w×4w	0	NR
Guo CH, 2016	CT/MRI	0	60 (20/20)	C:64.4±8.5 E:62.1±10.6	C:30.6±9.4 D E:33.1±8.6 D	R	SLT	SLT + rTMS	1	70% of the MT	IFG-R	30 min×6d/w4w	0	NR
Fan YN, 2016	CT/MRI	0	116 (58/58)	C:65.4±15.9 E:64.4±14.5	C:7.2±3.1 D E:6.9±3.3 D	R	ST + drug treatment	ST + drug treatment+rTMS	1	80% of the MT	IFG-R	20 min/d × 30d	0	NR
Shen Y, 2016	NR	0	40 (20/20)	C: 57.5±11.9 E:60.2±10.5	C:45.1 ± 18.8 D E:50.7 ± 16.3 D	R	drug treatment +ST	drug treatment +ST + rTMS	0.5	90% of the MT, 384 pulses	IFG-R	5d/w×3w	00	NR
ShanYD,2012	CT/MRI	NR	28 (14/14)	C:67.3±10.9 E:69.7±12.8	C:10.3±9.1W E:11.6±7.5W	R	SLT	SLT + rTMS	1	100% maximum intensity	IFG-R	20 min/d×10d	3	90D
Chen F, 2012	CT/MRI	NR	24 (12/12)	$C:65.5 \pm 2.5$ $E:66.5 \pm 1.8$	C/E: < 7 D	R	SLT	SLT + rTMS	1	80% of the MT	IFG-R	20 min/d×10d	2	2 W, 2 and 6 M
Chen F, 2011	CT/MRI	NR	15 (7/8)	C:66.5 E:65.7	C/E: <7 D	R	SLT	SLT + rTMS	1	80% MEP	IFG-R	10d	٢	NR

(Continued)

10.3389/fneur.2024.1348695

TABLE 1 (Continued)

Studies and year		nostic teria	Total patients (C/E)	Age (years)	Course of disease	Hand- edness	Interv	rention		rTMS paramet	ers	Duration	Outcome indicators	Follow up (after treatment)
	Stroke	Aphasia					С	E	FRQ (Hz)	Intensity	Stimulation sites			
Bing-Fong Lin, 2023	MRI	NR	33 (17/16)	C:62.24 \pm 14.42 E:54.06 \pm 12.12	C:12.18±12.63 M E:9.00±7.30 M	R	SLT + S-rTMS	SLT+rTMS	1	90% of the rMT, 900 pulses	IFG-R	$20 \min \times 5d/w \times 2w$	۲	NR
Trevor A. Low, 2023	NR	0	20 (10/10)	C:63.8±5.6 E:61.5±12.2	C:2.4 Y E:3.2 Y	R	M-MAT+ S-rTMS	M-MAT+rTMS	1	100% of the rMT,1,200 pulses	IFG-R	$20 \min/d \times 5d/w \times 2w$	6	3 M
Yaşa İ, C, 2023	MRI	T-RAT	40 (10/10)	C:60.00±5.05 E:59.70±5.31	C:10.4 M E:10.6 M	R	SLT	SLT+rTMS	1	110% of the MT, 1500 pulses	IFG-R	$20 \min/d \times 5d/w \times 3w$	ADD+ T-PNT	1 M
Guangtao Bai, 2022	CT/MRI	0	60 (30/30)	C:59.91±8.58 E:63.47±7.81	C:3.75±1.67 M E:3.27±1.50 M	R	CST+S-rTMS	CST + rTMS	1	80% of the MT	IFG-R	$20 \min/d \times 5d/w \times 4w$	0	NR
Kai Zheng, 2022	NR	0	40 (20/20)	40-80	C/E:>6 M	R	SLT + S-rTMS	SLT + rTMS	5	80% of the ATM	Crus I of the right lateral cerebellum	5d/w×2w	036	12 W
Bing-Fong Lin, 2022	MRI	(4)	33 (16/17)	$C:62.94 \pm 14.59$ $E:54.71 \pm 12.03$	C:12.63±12.9 M E:9.41±7.27 M	R	SLT + S-rTMS	SLT + rTMS	1	90% of the rMT, 900 pulses	IFG-R	$15 \min/d \times 5d/w \times 2w$	۲	NR
Eun-Ho Yu, 2021	MRI	1	20 (10/10)	$C:52.90 \pm 10.90$ $E:59.40 \pm 12.18$	C:4.63 ± 3.00 M E:5.17 ± 3.30 M	NR	SLT + IBA	SLT + NBA	1	90% of the rMT, 1,200 pulses	IFG-R	$20 \min \times 5 d/w \times 2w$	٥	NR
LA Lopez- Romero, 2019	NR	6	82 (41/41)	C:65.6±13.4 E:61.9±13.9	C:12.8 M E:9.21 M	R	S-rTMS	rTMS	1	80% of the MT, 1200 pulses	IFG-R	$20 \min \times 5 d/w \times 2w$	6	30D
Mohammad Haghighi, 2018	NR	NR	12 (6/6)	C: 60.5±11.85 E:61.67±7.06	C/E:4-8 W	NR	SLT + S-rTMS	SLT+rTMS	1	100% of the rMT	IFG-R	$30 \min \times 5 d/w \times 2w$	Ū	NR
Tae Hee Yoon, 2015	NR	NR	20 (10/10)	C:61.13±8.72 E:60.46±9.63	C:5.20±2.67 M E:6.80±2.39 M	NR	SLT	SLT+rTMS	1	90% of the rMT, 1,200 pulses	IFG-R	$20 \min \times 5 d/w \times 4w$	0	NR
Chih-Pin Wang, 2014	MRI	NR	45 (15/15)	C:60.4±11.9 E:61.3±13.2	C:16.1±7.3 M E:16.8±6.4 M	R	Naming task+ S-rTMS	Namingtask+ rTMS	1	90% of the rMT, 1,200 pulses	IFG-R	$20 \min \times 5d/w \times 2w$	۲	3 M
Po-Yi Tsai, 2014	MRI	NR	56 (23/33)	$C:62.8 \pm 14.5$ $E:62.3 \pm 12.1$	C:18.3±8.2M E:17.8±7.2M	R	SLT + S-rTMS	SLT + rTMS	1	90% of the rMT, 1,200 pulses	IFG-R	$10 \min \times 5 d/w \times 2w$	۲	3 M
Eman M. Khedr, 2014	NR	ASRS	30 (10/20)	C:57.4±9.6 E:61.0±9.8	C:4.0±2.6W E:5.8±4.08W	R	SLT + S-rTMS	SLT + rTMS	1 / 20	110% of the rMT, 1,000 pulses	right and left Broca	5d/w×2w	HSS	1 and 2 M
Caroline H.S, 2013	MRI	NR	12 (6/6)	specific age information for each patient	specific course of disease for each patient	R	S-rTMS	rTMS	1	90% of the rMT, 1,200 pulses	BA 45	20 min × 5d/w × 2w	Û©	2, 8, and 12 M

(Continued)

Studies and year	Diag cri	Diagnostic criteria	Total patients (C/E)	Age (years)	Course of disease	Hand- edness		Intervention		rTMS parameters	ers	Duration	Outcome indicators	Outcome Follow up indicators (after treatment)
	Stroke	Stroke Aphasia					U	ш	FRQ (Hz)	FRQ Intensity (Hz)	Stimulation sites			
Jared Medina,	NR	6	10 (5/5)	C:62.6±10.1	C: 58.6±34.8 D	NR	S-rTMS	rTMS	-	90% of the rMT, 1,200	IFG-R	5d/w×2w	Θ	2 M
2012				$E:60.6\pm7.1$	E: 49.8±29.6 D					pulses				
Barwood CH, NR	NR	NR	12 (6/6)	$C:60.8 \pm 5.98$	C: 3.49 ± 1.27 Y	R	S-rTMS	rTMS	1	1 1,200 pulses	BA45	$20 \min \times 10d$	00	2 M
2011				$E{:}67\pm13.22$	E: 4.46 ± 1.53 Y									
C, control group	; E, experime	nt group; FRQ), frequency; NF	R, not reported; L,	left; R, right; D/d, d	lays; W/w, we	eks; M, month/mont	ths; Intensity: MT, moto	or threshol	C, control group; E, experiment group; FRQ, frequency; NR, not reported; L, left; R, right; D/d, days; W/w, weeks; M, month/months; Intensity: MT; motor threshold; rMT; resting motor threshold; AMT, active motor threshold; Intervention: SIT; speech-language	shold; AMT, active	motor threshold; Inter	vention: SLT, spee	ch-language
gyrus; IFG-L, lef	t inferior fror.	ital gyrus; PST	G-R, right post	erior superior ten	nvenuonai speech u nooral gyrus: BA45,	Brodmann 4	5: IBA, involvement (of Broca's area: NBA, no	-y apitabid nn-IBA; O	истаруу 5-т.1 мо. знаи герецие салысшан пависих смитанов, с.5. контепноват уссси истару, просли устариала истару, т.5. чесскоа принсцист, м.; ношие истанист, элинанов мез. г. Ск. вуп листов пона. гупк: IFG-L. left inferier frontal gyrus: PSTG-R. right posterior superior temporal gyrus: BA45. Boodmann 45. IBA, involvement of Broca's area: NBA, non-IBA; Outcome indicators: @WAB. Western Abhasia Battery of Chinese: @CRRCAE.	. Western Aphasia B	attery; @ABC, Aphasi	a Batterv of Chines	ILLET OF LIGHTAL

China Rehabilitation Re-search Center Standard Aphasia Examination; @CCAT, Concise Chinese Aphasia Test; @BDAF, Boston Diagnostic Aphasia Examination; @BNT, Boston Naming Test; @MBI, Modified Barthel Index; @MMSE, Mini-mental State Examination; @NIHSS, National Institutes of Health Stroke Scale; @HAMD, Hamilton Rating Scale for Depression; (D/CADL, Comprehensive Activities of Daily Living; (2)FIM, Functional Independence Measure

Meta-analysis

A total of 12 studies were excluded from this meta-analysis due to the following reasons. Specifically, the outcomes of two studies (71, 73) were shown as bar graphs, and two (66, 74) were presented as line charts rather than specific values. Individual outcome indicators in four studies (56, 58, 67, 74) could not be integrated with other studies. Zheng's (77) date was unacquirable. Data in three studies (62-64) of Zhu was described by Median and quartile which could not be counted. Finally, a total of 35 studies were included.

Aphasia quotient

Fifteen studies (23, 36-38, 41, 42, 44, 46, 51, 52, 57, 59, 61, 65, 75) involving 960 patients assessed aphasia quotient (AQ) in patients after rTMS stimulation. The random-effects model was utilized due to significant heterogeneity across the studies ($I^2 = 78\%$). Global language ability of the rTMS-treated group exhibited a substantial improvement in comparison to the control group [p < 0.00001](Figure 1). Subgroup analysis was conducted according to the stroke stages of patients after removing a study (50) with unidentified stroke duration and another study (75) that patients were in the sequelae stage. The random-effects model was employed for the following studies: three studies (37, 41, 44) with patients in the acute phase [SMD = 1.41, 95% CI (0.91, 1.91), *p* < 0.00001, *I*² = 78%] and 11 studies (23, 36, 38, 42, 46, 51, 52, 57, 59, 61, 65) with patients in the recovery stage [p < 0.00001, $I^2 = 77\%$] (Figure 2). Upon conducting sensitivity analysis, the removal of two studies (36, 57) from the subgroup of recovery, the following outcomes were observed: 9 studies (23, 38, 42, 46, 51, 52, 59, 61, 65) of recovery subgroup $[p < 0.00001, I^2 = 0\%]$ (Figure 3). The findings suggest that rTMS has the potential to enhance the overall language abilities of stroke patients during both acute and recovery phases.

Repetition

Twenty-two studies (23, 36-39, 41-44, 46, 48-52, 55, 59, 61, 65, 68, 69, 75) involving 1,228 patients assessed repetition ability in patients after rTMS treatment. The random-effects model was utilized due to significant heterogeneity across the studies ($I^2 = 85\%$). Repetition ability of rTMS-treated group exhibited a substantial improvement in comparison to the control group [p < 0.00001](Figure 4). Subgroup analysis was conducted according to the stroke stages of patients after removing a study (50) with unidentified stroke duration. The random-effects model was employed for the following studies: four studies (37, 41, 44, 59) with patients in the acute stage $[p < 0.00001, I^2 = 84\%]$. The fixed-effects model was employed for the following studies: 14 studies (23, 36, 38, 39, 42, 43, 46, 48, 49, 51, 52, 55, 61, 65) with patients in the recovery stage $[p < 0.00001, I^2 = 41\%]$ and three studies (68, 69, 75) with patients in the sequelae stage $[p=0.005, I^2=0\%]$ (Figure 5). These findings suggest that rTMS enhance repetition abilities in patients across various stages of stroke recovery. Notably, beyond immediate benefits, rTMS appears to exert medium- to long-term effects on language improvement. For individuals with NFA post-stroke, the positive effects of rTMS on speech enhancement persisted for up to 12 months (66).

TABLE 1 (Continued)

Bai GT, 2022 52 Cao HY, 2023 19 Chang L, 2018 7 Fan YN, 2016 7 Guo CH, 2016 6 Haghight M, 2018 50 Li WT, 2021 76 Li WT, 2021 63	lean S 2.62 25.0 9.77 4.8 77.2 8 75.9 8 1.78 11.4 0.27 28.3 6.38 18.3	2 30 4 30 6 63 1 58 5 20 7 6	8.8 64.5 63.4 54.42	SD 20.51 2.55 7.1 6.2 11.13	Total 28 30 63 58	Weight 7.2% 6.1% 7.9%	IV, Random, 95% Cl 0.65 [0.12, 1.18] 2.80 [2.07, 3.52] 1.60 [1.20, 2.00]	IV, Random, 95% CI
Cao HY, 2023 19 Chang L, 2018 7 Fan YN, 2016 7 Guo CH, 2016 61 Haghighi M, 2018 50 Li WT, 2021 76 Li WJ, 2023 63	9.77 4.8 77.2 8 75.9 8 1.78 11.4 0.27 28.3	4 30 6 63 1 58 5 20 7 6	8.8 64.5 63.4 54.42	2.55 7.1 6.2	30 63	6.1% 7.9%	2.80 [2.07, 3.52]	
Chang L, 2018 7 Fan YN, 2016 7 Guo CH, 2016 61 Haghighi M, 2018 50 Li WT, 2021 76 Liu SJ,2023 63	77.2 8 75.9 8 1.78 11.4 0.27 28.3	6 63 1 58 5 20 7 6	64.5 63.4 54.42	7.1 6.2	63	7.9%		
Fan YN, 2016 7 Guo CH, 2016 61 Haghighi M, 2018 50 Li WT, 2021 76 Liu SJ,2023 63	75.9 8 1.78 11.4 0.27 28.3	1 58 5 20 7 6	63.4 54.42	6.2			1.60 [1.20, 2.00]	
Guo CH, 2016 61 Haghighi M, 2018 50 Li WT, 2021 76 Liu SJ,2023 63	1.78 11.4 0.27 28.3	5 20 7 6	54.42		58			
Haghighi M, 2018 50 Li WT, 2021 76 Liu SJ,2023 63	0.27 28.3	76		11.13		7.7%	1.72 [1.29, 2.15]	
Li WT, 2021 76 Liu SJ,2023 63		-	00.0		20	6.6%	0.64 [0.00, 1.28]	
Liu SJ,2023 63	6.38 18.3		39.3	18.14	6	4.0%	0.43 [-0.73, 1.58]	
		4 60	60.31	16.22	60	8.0%	0.92 [0.55, 1.30]	
000 L F 0000 FF	3.27 9.1	8 46	54.68	8.97	46	7.7%	0.94 [0.51, 1.37]	
Qiu LF, 2020 55	5.65 5.5	7 19	46.66	11.71	19	6.3%	0.96 [0.28, 1.64]	
Qu YZ, 2020 53	3.05 18.7	5 20	43.04	10.13	20	6.6%	0.65 [0.01, 1.29]	
Shen Y, 2016 63	3.66 13.6	4 20	45.31	14.12	20	6.3%	1.30 [0.61, 1.98]	
Tae Hee Yoon, 2015 60	0.14 21.3	7 10	59.32	21.49	10	5.3%	0.04 [-0.84, 0.91]	
Xu DM, 2022 2	23.5 2	4 30	19.3	1	30	6.5%	2.25 [1.60, 2.91]	
Zhang Y, 2019 65	5.18 16.2	2 16	53.92	13.99	16	6.1%	0.72 [0.01, 1.44]	
Zhou HY, 2021 66	6.27 15.3	4 53	52.83	12.07	53	7.9%	0.97 [0.56, 1.37]	
Total (95% CI)		481			479	100.0%	1.13 [0.82, 1.44]	•
Heterogeneity: Tau ² = 0.28	8; Chi ² = 6	.34, df =	14 (P <	0.0000	1); I ² = 3	78%	-	
Test for overall effect: Z = 7	7.17 (P < (.00001)						Favors Control Favors rTMS

		rTMS			Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
2.4.1 acute stage									
Chang L, 2018	77.2	8.6	63	64.5	7.1	63	8.4%	1.60 [1.20, 2.00]	
Fan YN, 2016	75.9	8.1	58	63.4	6.2	58	8.2%	1.72 [1.29, 2.15]	
Li WT, 2021	76.38	18.34	60	60.31	16.22	60	8.5%	0.92 [0.55, 1.30]	
Subtotal (95% CI)			181			181	25.1%	1.41 [0.91, 1.91]	
Heterogeneity: Tau ² =	= 0.15; C	hi² = 9.2	6, df=	2 (P = 0	.010); P	= 78%			
Test for overall effect	Z = 5.52	? (P < 0.	00001)						
2.4.2 recovery stage									
Bai GT, 2022	52.62	25.02	30	37.46	20.51	28	7.6%	0.65 [0.12, 1.18]	
Cao HY, 2023	19.77	4.84	30	8.8	2.55	30	6.3%	2.80 [2.07, 3.52]	
Guo CH, 2016	61.78	11.45	20	54.42	11.13	20	6.9%	0.64 [0.00, 1.28]	
Haghighi M, 2018	50.27	28.37	6	39.3	18.14	6	4.1%	0.43 [-0.73, 1.58]	
Liu SJ,2023	63.27	9.18	46	54.68	8.97	46	8.2%	0.94 [0.51, 1.37]	
Qiu LF, 2020	55.65	5.57	19	46.66	11.71	19	6.7%	0.96 [0.28, 1.64]	
Qu YZ, 2020	53.05	18.75	20	43.04	10.13	20	6.9%	0.65 [0.01, 1.29]	
Shen Y, 2016	63.66	13.64	20	45.31	14.12	20	6.6%	1.30 [0.61, 1.98]	
Xu DM, 2022	23.5	2.4	30	19.3	1	30	6.8%	2.25 [1.60, 2.91]	→
Zhang Y, 2019	65.18	16.22	16	53.92	13.99	16	6.4%	0.72 [0.01, 1.44]	
Zhou HY, 2021	66.27	15.34	53	52.83	12.07	53	8.4%	0.97 [0.56, 1.37]	
Subtotal (95% CI)			290			288	74.9%	1.12 [0.74, 1.51]	
Heterogeneity: Tau ² =	= 0.32; C	hi² = 43	46, df=	= 10 (P ·	< 0.000	01); I ² =	77%		
Test for overall effect	Z = 5.70) (P < 0.	00001)						
Total (95% CI)			471			469	100.0%	1.19 [0.89, 1.50]	•
Heterogeneity: Tau ² =	= 0.25: C	hi² = 56	.86. df=	= 13 (P	< 0.000	01); ² =	77%		
Test for overall effect									-2 -1 0 1 2
Test for subaroup dif					= 0.38).	l ² = 0%	6		Favors Control Favors rTMS
RE 2 asia quotient after rT									

Naming

Twenty-two (23, 36–38, 41–44, 46, 48–52, 55, 59–61, 65, 68, 69, 75) studies involving 1,229 patients evaluated naming ability in patients after rTMS. The random-effects model was utilized due to significant heterogeneity across the studies ($I^2 = 86\%$). Naming ability of the rTMS-treated group exhibited a substantial improvement in comparison to the control group [p < 0.00001] (Figure 6). Subgroup analysis was conducted according to the stroke stages of patients after

removing a study (50) with unidentified stroke duration. The randomeffects model was employed for the following studies: four studies (37, 41, 44, 59) with patients in the acute stage [p < 0.00001, $l^2 = 83\%$]. The fixed-effects model was employed for the following studies: 14 studies (23, 36, 38, 42, 43, 46, 48, 49, 51, 52, 55, 59, 61, 65) with patients in the recovery stage of [p < 0.00001, $l^2 = 1\%$] and three studies (68, 69, 75) with patients in the sequelae stage [p = 0.0003, $l^2 = 0\%$] (Figure 7). Naming is among the most challenging functions for stroke patients with NFA to regain. The restoration of naming capabilities necessitates

~		rTMS	.		Control	T	-	td. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
Bai GT, 2022	52.62	25.02	30	37.46	20.51	28	13.2%	0.65 [0.12, 1.18]	
Guo CH, 2016	61.78	11.45	20	54.42	11.13	20	9.1%	0.64 [0.00, 1.28]	
Haghighi M, 2018	50.27	28.37	6	39.3	18.14	6	2.8%	0.43 [-0.73, 1.58]	
Liu SJ,2023	63.27	9.18	46	54.68	8.97	46	19.9%	0.94 [0.51, 1.37]	
Qiu LF, 2020	55.65	5.57	19	46.66	11.71	19	8.1%	0.96 [0.28, 1.64]	
Qu YZ, 2020	53.05	18.75	20	43.04	10.13	20	9.1%	0.65 [0.01, 1.29]	
Ren CL, 2018	63.66	13.64	20	45.31	14.12	20	7.8%	1.30 [0.61, 1.98]	
Zhang Y, 2019	65.18	16.22	16	53.92	13.99	16	7.2%	0.72 [0.01, 1.44]	
Zhou HY, 2021	66.27	15.34	53	52.83	12.07	53	22.8%	0.97 [0.56, 1.37]	
Total (95% Cl)			230			228	100.0%	0.85 [0.66, 1.05]	•
Heterogeneity: Chi ² =	4.17, df	= 8 (P =	0.84);	l² = 0%				+	
Test for overall effect	Z = 8.69	(P < 0.)	00001)					-2	-1 U 1 2
		(· - ·	,						Favors Control Favors rTMS

Aphasia quotient of stroke patients in the recovery stage (sensitivity analysis).

	r	TMS		0	Control		1	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Bai GT, 2022	5.56	3.04	28	3.97	2.91	30	4.9%	0.53 [0.00, 1.05]	
Cao HY, 2023	2.03	1.16	30	0.8	0.33	30	4.8%	1.42 [0.85, 1.99]	
Chang L, 2018	9	1.3	63	7.1	1.2	63	5.2%	1.51 [1.11, 1.91]	
Chen Y, 2020	24	2	14	19	9	15	4.3%	0.73 [-0.02, 1.49]	
Fan YN, 2016	8.9	1.3	58	7	1.1	58	5.1%	1.57 [1.15, 1.99]	
Guo CH, 2016	5.76	1.57	20	5.18	1.53	20	4.6%	0.37 [-0.26, 0.99]	
Haghighi M, 2018	4.67	3.98	6	2.58	3.88	6	3.3%	0.49 [-0.67, 1.65]	
Jiang XC,2023	133.14	27.1	22	89.35	21.96	23	4.5%	1.75 [1.05, 2.44]	
Li WT, 2021	8.31	0.72	60	7.63	1.43	60	5.2%	0.60 [0.23, 0.96]	
Lin BF, 2022	7.98	2.73	16	5.57	3.22	17	4.4%	0.79 [0.07, 1.50]	
Lin BF, 2023	7.69	2.89	17	5.73	3.26	16	4.5%	0.62 [-0.08, 1.32]	
Liu SJ,2023	69.71	14.8	46	60.35	13.09	46	5.1%	0.66 [0.24, 1.08]	
Pan LS, 2019	7.15	1.98	20	5.73	1.98	22	4.6%	0.70 [0.08, 1.33]	
Qiao Y, 2019	7.15	1.49	20	6.27	1.23	22	4.7%	0.63 [0.01, 1.26]	
Qin Q, 2020	84.05	1.31	38	75.54	1.14	38	3.2%	6.86 [5.65, 8.07]	•
Qiu LF, 2020	63.27	15.8	17	53.11	22.26	19	4.5%	0.51 [-0.16, 1.18]	
Qu YZ, 2020	53.25	24.94	20	40.95	13.16	20	4.6%	0.60 [-0.03, 1.24]	
Shen Y, 2016	82.65	15.14	20	55.85	21.64	20	4.5%	1.41 [0.71, 2.11]	
Tae Hee Yoon, 2015	68.8	20.47	10	59.6	23.43	10	4.0%	0.40 [-0.49, 1.29]	
Wang JR, 2018	72	23.74	15	52.67	27	15	4.3%	0.74 [-0.00, 1.48]	
Zhang Y, 2019	83.91	18.2	16	74.43	21.03	16	4.5%	0.47 [-0.23, 1.17]	
Zhou HY, 2021	84.85	18.31	53	75.54	22.14	53	5.2%	0.45 [0.07, 0.84]	
Total (95% CI)			609			619	100.0%	1.01 [0.68, 1.34]	•
Heterogeneity: Tau ² = I	0.51; Chi²	= 144.5	5, df =	21 (P <	0.00001	1); I² = 3	85%		+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$
Test for overall effect: 2	Z = 6.00 (F	° < 0.00	001)						Favors Control Favors rTMS
RE 4									
etition capability after	TMC								

the involvement of extensive neural networks, and rTMS has been shown to facilitate the recovery of these abilities across various stages of stroke, primarily by enhancing the connectivity among pertinent brain areas (65).

Spontaneous language

Seventeen studies (4, 23, 36–38, 41, 42, 44, 46, 48, 50–52, 55, 59, 61, 65) involving 1,046 patients assessed spontaneous language ability in patients after rTMS stimulation. The random-effects model was utilized due to significant heterogeneity across the studies ($l^2 = 67\%$). Spontaneous language ability of the rTMS-treated group exhibited a substantial improvement in comparison to the control group [p < 0.00001] (Figure 8). Subgroup analysis was conducted according

to the stroke stages of patients after removing a study (50) with unidentified stroke duration and another study (75) that patients were in the sequelae stage. The random-effects model was employed for the following studies: four studies (37, 41, 44, 59) with patients in the acute stage [p < 0.00001, $I^2 = 64\%$]. The fixed-effects model was utilized for the following studies: 11 studies (23, 36, 38, 42, 46, 48, 51, 52, 55, 61, 65) with patients in the recovery stage [p < 0.00001, $I^2 = 0\%$] (Figure 9). These results suggested that rTMS ameliorated spontaneous language capability in patients in acute and recovery stages. Acupuncture therapy constitutes a significant component of complementary and alternative medicine, which has potential therapeutic effects in the treatment of PSA (81). The combined therapeutic application of acupuncture and rTMS on NFA has demonstrated a markedly superior efficacy compared to monotherapy. Specifically, the overall effectiveness of combining 1 Hz

tudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	Std. Mean Difference IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
.3.1 acute stage	mean	- 50	Total	mean	- 50	Total	weight		
hang L, 2018	9	1.3	63	7.1	1.2	63	9.5%	1.51 [1.11, 1.91]	
an YN, 2016	8.9	1.3	58	7	1.1	58	3.5% 8.6%	1.57 [1.15, 1.99]	>
i WT, 2021	8.31	0.72	60	7.63	1.43	60	11.2%	0.60 [0.23, 0.96]	
(hang Y, 2019	83.91	18.2		74.43		16	3.0%	0.47 [-0.23, 1.17]	
ubtotal (95% CI)	03.91	10.2	197	74.43	21.05	197		1.11 [0.90, 1.33]	•
leterogeneity: Chi² = 1	0.00 46-	2 /0 - 1		12 - 04	ov.	197	JZ.J70	1.11[0.90, 1.55]	•
				, 1- = 84	70				
est for overall effect: 2	2=10.111	(P < 0.0	0001)						
.3.2 recovery stage									
ai GT, 2022	5.56	3.04	28	3.97	2.91	30	5.4%	0.53 [0.00, 1.05]	
ao HY, 2023	2.03	1.16	30	0.8	0.33	30	4.6%	1.42 [0.85, 1.99]	
hen Y, 2020	2.03	2	14	19	0.55	15	4.0% 2.6%	0.73 [-0.02, 1.49]	
Suo CH, 2016	5.76	1.57	20	5.18	1.53	20	3.8%	0.37 [-0.26, 0.99]	
laghighi M, 2018	4.67	3.98	20	2.58	3.88	20	1.1%	0.49 [-0.67, 1.65]	
iang XC,2023	133.14	27.1		89.35		23	3.1%	1.75 [1.05, 2.44]	
iu SJ,2023	69.71	14.8		60.35		46	3.1% 8.5%	0.66 [0.24, 1.08]	
'an LS, 2019	7.15	1.98	20	5.73	1.98	22	3.8%		
iao Y, 2019	7.15	1.90	20	6.27	1.90	22	3.0% 3.9%	0.70 [0.08, 1.33] 0.63 [0.01, 1.26]	
	63.27	1.49		53.11		19	3.9%		
iu LF, 2020				53.11 40.95				0.51 [-0.16, 1.18]	
0u YZ, 2020		24.94				20	3.7%	0.60 [-0.03, 1.24]	
hen Y, 2016		15.14		55.85		20	3.1%	1.41 [0.71, 2.11]	,
Vang JR, 2018		23.74		52.67	27	15	2.7%	0.74 [-0.00, 1.48]	
hou HY, 2021	84.85	18.31		75.54	22.14	53		0.45 [0.07, 0.84]	
ubtotal (95% CI)	0.00 46	40.00	331	17 440	,	341	59.8%	0.74 [0.58, 0.90]	•
leterogeneity: Chi ² = 2				I* = 419	ò				
est for overall effect: 2	2 = 9.18 (F	, < 0.00	001)						
.3.3 sequelae stage									
in BF, 2022	7.98	2.73	16	5.57	3.22	17	3.0%	0.79 [0.07, 1.50]	
in BF, 2023	7.69	2.89	17	5.73	3.26	16	3.0%	0.62 [-0.08, 1.32]	
ae Hee Yoon, 2015		20.47	10		23.43	10	1.9%	0.40 [-0.49, 1.29]	
ubtotal (95% CI)	00.0	20.47	43	55.0	20.40	43	7.9%	0.63 [0.19, 1.07]	
leterogeneity: Chi² = (144 df= 1	7/P – n		- ೧%		45	1.370	0.05 [0.13, 1.07]	
est for overall effect: 2		- ·	/	- 0 %					
estilui overall ellect. A	L – 2.04 (F	- 0.00	3)						
otal (95% CI)			571			581	100.0%	0.85 [0.73, 0.97]	•
leterogeneity: Chi ² = :	50.32.df=	20 (P =		2): I ² = 6	0%				
est for overall effect: 2									-1 -0.5 0 0.5 1
est for subaroup diffe				2(P = 1)	1.01) F	= 76.39	8		Favours Control Favours rTMS
control caparoan ame		0.	ur –			. 0.0			

	1	rTMS		0	ontrol		5	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Bai GT, 2022	4.96	2.49	28	3.39	2.17	30	4.9%	0.66 [0.13, 1.19]	
Cao HY, 2023	1.23	0.54	30	0.68	0.19	30	4.9%	1.34 [0.78, 1.90]	
Chang L, 2018	8.4	2.3	63	6.8	2.2	63	5.3%	0.71 [0.35, 1.07]	
Fan YN, 2016	8.3	2	58	6.7	1.9	58	5.2%	0.81 [0.44, 1.19]	
Guo CH, 2016	5.82	1.53	20	5.24	1.57	20	4.7%	0.37 [-0.26, 0.99]	
Haghighi M, 2018	4.5	4.22	6	3.33	4.09	6	3.5%	0.26 [-0.88, 1.40]	
Jiang XC,2023	90.86	33.11	22	51	27.84	23	4.7%	1.28 [0.64, 1.93]	
Li WT, 2021	5.38	0.63	60	4.31	0.53	60	5.2%	1.83 [1.40, 2.25]	
Lin BF, 2022	7.49	3.5	16	4.65	3.02	17	4.5%	0.85 [0.13, 1.57]	
Lin BF, 2023	7.28	3.5	17	4.76	3.09	16	4.5%	0.74 [0.03, 1.45]	
Liu SJ,2023	59.65	13.26	46	46.95	13.08	46	5.1%	0.96 [0.52, 1.39]	
Pan LS, 2019	12.85	3.23	20	10.41	3.25	22	4.7%	0.74 [0.11, 1.37]	
Qiao Y, 2019	12.33	2.43	20	10.64	2.82	22	4.7%	0.63 [0.01, 1.25]	
Qin Q, 2020	76.74	1.82	38	54.86	1.01	38	1.5%	14.71 [12.27, 17.16]	•
Qiu LF, 2020	48.18	13.78	17	37.89	14.76	19	4.6%	0.70 [0.03, 1.38]	
Qu YZ, 2020	49.6	22.87	20	37.75	13.67	20	4.7%	0.62 [-0.02, 1.25]	
Shen Y, 2016	81.28	22.12	20	57.6	24.42	20	4.6%	1.00 [0.34, 1.66]	
Tae Hee Yoon, 2015	65	12.38	10	51.4	17.52	10	4.0%	0.86 [-0.07, 1.78]	
Wang JR, 2018	42.83	16.14	15	26.26	20.18	15	4.4%	0.88 [0.13, 1.64]	
Zhang Y, 2019	75.63	21.71	16	53.75	21.9	16	4.5%	0.98 [0.24, 1.72]	
Zheng Y, 2022	45.53	10.66	15	37.43	8.62	15	4.4%	0.81 [0.06, 1.56]	
Zhou HY, 2021	76.54	19.68	53	54.22	16.13	53	5.2%	1.23 [0.81, 1.65]	
Total (95% CI)			610			619	100.0%	1.09 [0.74, 1.43]	•
Heterogeneity: Tau ² = (0.56; Chi	i ² = 154.	23, df=	= 21 (P ·	< 0.0000	01); I ² =	86%		
Test for overall effect: Z	Z = 6.15 ((P < 0.0	0001)						-2 -1 U 1 2 Favors Control Favors rTMS
IRE 6									
ning capability after rT	MS.								

Frontiers in Neurology

Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% CI
2.1.1 acute stage									
Chang L, 2018	8.4	2.3	63	6.8	2.2	63	11.6%	0.71 [0.35, 1.07]	
Fan YN, 2016	8.3	2	58	6.7	1.9	58	10.5%	0.81 [0.44, 1.19]	
Li WT, 2021	5.38	0.63	60	4.31	0.53	60	8.2%	1.83 [1.40, 2.25]	
Zhang Y, 2019	75.63	21.71	16	53.75	21.9	16	2.8%	0.98 [0.24, 1.72]	
Subtotal (95% CI)			197			197	33.1%	1.04 [0.83, 1.26]	•
Heterogeneity: Chi ² = 1	17.63, df	= 3 (P =	0.000	5); l² = 8	3%				
Test for overall effect: 2	Z = 9.57 ((P < 0.0	0001)						
2.1.2 recovery stage									
Bai GT, 2022	4.96	2.49	28	3.39	2.17	30	5.4%	0.66 [0.13, 1.19]	
Cao HY, 2023	1.23	0.54	30	0.68	0.19	30	4.8%	1.34 [0.78, 1.90]	
Guo CH, 2016	5.82	1.53	20	5.24	1.57	20	3.9%	0.37 [-0.26, 0.99]	- +
Haghighi M, 2018	4.5	4.22	6	3.33	4.09	6	1.2%	0.26 [-0.88, 1.40]	
Jiang XC,2023	90.86	33.11	22	51	27.84	23	3.6%	1.28 [0.64, 1.93]	
Liu SJ,2023	59.65	13.26	46	46.95	13.08	46	8.1%	0.96 [0.52, 1.39]	
Pan LS, 2019	12.85	3.23	20	10.41	3.25	22	3.8%	0.74 [0.11, 1.37]	
Qiao Y, 2019	12.33	2.43	20	10.64	2.82	22	3.9%	0.63 [0.01, 1.25]	
Qiu LF, 2020	48.18	13.78	17	37.89	14.76	19	3.3%	0.70 [0.03, 1.38]	
Qu YZ, 2020	49.6	22.87	20	37.75	13.67	20	3.7%	0.62 [-0.02, 1.25]	
Shen Y, 2016	81.28	22.12	20	57.6	24.42	20	3.5%	1.00 [0.34, 1.66]	
Wang JR, 2018	42.83	16.14	15	26.26	20.18	15	2.7%	0.88 [0.13, 1.64]	
Zhang Y, 2019	75.63	21.71	16	53.75	21.9	16	2.8%	0.98 [0.24, 1.72]	
Zhou HY, 2021	76.54	19.68		54.22	16.13	53	8.7%	1.23 [0.81, 1.65]	
Subtotal (95% CI)			333			342	59.2%	0.90 [0.74, 1.06]	•
Heterogeneity: Chi² = 1					6				
Test for overall effect: 2	Z = 11.01	(P ≤ 0.	00001)						
2.1.4 sequelae stage									
Lin BF, 2022	7.49	3.5	16	4.65	3.02	17	2.9%	0.85 [0.13, 1.57]	
Lin BF, 2023	7.28	3.5	17	4.76	3.09	16	3.0%	0.74 [0.03, 1.45]	
Tae Hee Yoon, 2015	65	12.38	10	51.4	17.52	10	1.8%	0.86 [-0.07, 1.78]	
Subtotal (95% CI)			43			43	7.7%	0.81 [0.37, 1.25]	
Heterogeneity: Chi ² = (= 0%					
Test for overall effect: 2	Z = 3.59 ((P = 0.0	003)						
Total (95% CI)			573			582	100.0%	0.94 [0.82, 1.06]	•
Heterogeneity: Chi ² = 3					%				-2 -1 0 1 2
Test for overall effect: 2 Test for subaroup diffe					0.48). I	²= 0%			Favors Control Favors rTMS
RE 7									

Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Bai GT, 2022	9.93	5.24	30	6.68	4.46	28	6.4%	0.66 [0.13, 1.19]	
Cao HY, 2023	3.1	1.09	30	1.8	0.71	30	6.1%	1.39 [0.83, 1.96]	
Chang L, 2018	10.5	1.5	63	8.3	1.3	63	7.4%	1.56 [1.16, 1.96]	
Fan YN, 2016	10.2	1.6	58	8.2	1.2	58	7.4%	1.40 [1.00, 1.81]	
Guo CH, 2016	10.85	1.87	20	9.35	1.93	20	5.6%	0.77 [0.13, 1.42]	 →→
Haghighi M, 2018	6.34	3.21	6	2.67	1.32	6	2.4%	1.38 [0.06, 2.70]	
Li WT, 2021	14.61	1.71	60	11.45	1.47	60	7.1%	1.97 [1.53, 2.41]	
Liu SJ,2023	11.64	2.03	46	9.39	1.98	46	7.1%	1.11 [0.67, 1.55]	
Pan LS, 2019	4.05	1.1	20	3.09	1.15	22	5.7%	0.84 [0.20, 1.47]	—
Qin Q, 2020	9.24	1.12	38	7.11	1.36	38	6.4%	1.69 [1.16, 2.22]	
Qiu LF, 2020	10.35	1.77	17	8.47	3.13	19	5.4%	0.71 [0.04, 1.39]	
Qu YZ, 2020	7.8	4.35	20	5.45	2.35	20	5.6%	0.66 [0.02, 1.30]	
Shen Y, 2016	7.4	3.23	20	5.85	1.87	20	5.7%	0.58 [-0.06, 1.21]	<u>+</u>
Tae Hee Yoon, 2015	13	2.73	10	12.3	4.32	10	4.1%	0.19 [-0.69, 1.06]	
Wang JR, 2018	17.93	3.45	15	15.47	3	15	4.9%	0.74 [-0.00, 1.48]	
Zhang Y, 2019	9.13	3.01	16	7	2.25	16	5.1%	0.78 [0.06, 1.50]	
Zhou HY, 2021	8.25	2.13	53	6.73	2.14	53	7.5%	0.71 [0.31, 1.10]	
Total (95% CI)			522			524	100.0%	1.04 [0.81, 1.28]	•
Heterogeneity: Tau ² =	0.16; Chi	² = 47	.94, df=	= 16 (P ·	< 0.00	01); I ^z =	67%		
Test for overall effect: 2	Z = 8.58 (P < 0.	00001)						-2 -1 U 1 2 Favors Control Favors rTMS

FIGURE 8

Spontaneous language capability after rTMS.

~	-	TMS		_	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	lotal	Mean	SD	lotal	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
2.2.1 acute stage									
Chang L, 2018	10.5	1.5	63	8.3	1.3	63	12.0%	1.56 [1.16, 1.96]	
Fan YN, 2016	10.2	1.6	58	8.2	1.2	58	11.5%	1.40 [1.00, 1.81]	
Li WT, 2021	14.61			11.45		60	10.0%	1.97 [1.53, 2.41]	
Zhang Y, 2019	9.13	3.01	16	7	2.25	16	3.7%	0.78 [0.06, 1.50]	
Subtotal (95% CI)			197			197	37.2%	1.54 [1.32, 1.77]	
Heterogeneity: Chi ² =	•				%				
Test for overall effect	: Z = 13.3	12 (P <	0.0000)1)					
2.2.2 recovery stage Bai GT, 2022	9.93	5.24	30	6.68	4.40	20	6.8%	0 66 10 40 4 40	
		5.24 1.09				28	0.8% 5.9%	0.66 [0.13, 1.19]	
Cao HY, 2023 Guo CH, 2016	3.1 10.85		30	9.35		30 20	5.9% 4.6%	1.39 [0.83, 1.96]	
Haghighi M, 2018	6.34		20 6	9.35		20	4.6%	0.77 [0.13, 1.42]	_
Liu SJ,2023	0.34 11.64		46	9.39		46	9.9%	1.38 [0.06, 2.70] 1.11 [0.67, 1.55]	
Pan LS, 2019	4.05	2.03	20	3.09		22	9.9%	0.84 [0.20, 1.47]	
Qiu LF, 2020	4.05		17	8.47		19	4.0%	0.84 [0.20, 1.47] 0.71 [0.04, 1.39]	
Qu YZ, 2020		4.35	20	5.45		20	4.2%	0.66 [0.02, 1.30]	
Shen Y, 2016		3.23	20	5.85		20	4.8%	0.58 [-0.06, 1.21]	
Wang JR, 2018	17.93			15.47	3	15	3.5%	0.74 [-0.00, 1.48]	·
Zhou HY, 2021	8.25		53	6.73	-	53	12.4%	0.71 [0.31, 1.10]	
Subtotal (95% CI)	0.20	2.10	277	0.75	2.14	279	62.8%		•
Heterogeneity: Chi ² =	7 90 df	= 10 ($4) \cdot \mathbf{I}^2 = 0$	%	2.0			
Test for overall effect									
	0.10			/					
Total (95% CI)			474			476	100.0%	1.11 [0.97, 1.24]	•
Heterogeneity: Chi ² =	: 39.03, d	lf = 14	(P = 0.)	0004); P	²= 649	6		-	-2 -1 0 1 2
Test for overall effect	: Z = 15.8	i4 (P <	0.0000)1)					-2 -1 0 1 2 Favors Control Favors rTMS
Test for subaroup dif	ferences	: Chi²:	= 22.78	l. df = 1	(P < 0.	00001)	. I ² = 95.6	3%	
25.0									
RE 9								o different stroke stages.	

rTMS with acupuncture for NFA reached 96.66%, strongly associated with enhanced blood flow velocity and perfusion in the left middle cerebral artery (MCA) (44). Interaction between various acupuncture techniques and rTMS frequencies in producing distinct clinical outcomes warrants further investigation.

BDNF

Two studies (43, 65) involving 103 patients assessed the concentration of brain-derived neurotrophic factor (BDNF) within patients. The fixed-effects model was utilized due to low heterogeneity across the studies ($I^2 = 0\%$). The rTMS-treated group exhibited a substantial enhancement in serum BDNF concentration in comparison to the control group [p < 0.00001] (Figure 10). The findings indicated that rTMS has the potential to elevate the concentration of BDNF in the serum of stroke patients.

Mood

Two studies (48, 49) involving 84 patients used the Hamilton Depression Scale (HAMD) to evaluate the effects of rTMS on mood in stroke patients. The fixed-effects model was utilized due to low heterogeneity across the studies ($I^2 = 0\%$). The HAMD score of rTMS group was notably lower in comparison to the control group [p = 0.0005] (Figure 11). The findings indicated that rTMS had potential to ameliorate the depression of these patients.

Discussion

Numerous research groups, including those led by Naeser, Hamilton, Heiss, and Thiel, have showcased the effectiveness of rTMS in the treatment of PSA through significant studies. Despite their contributions, these studies were excluded from the review for various reasons. Hamilton's research indicated that rTMS offers sustained enhancements in picture naming and fluency in patients with NFA. However, limitations included the absence of a control group in one study (82) and crossover of sham group participants to actual rTMS treatment in another (71). Heiss and Thiel observed a delayed beneficial impact of LF-rTMS on the right pars triangularis (R IFG pr) in enhancing naming ability in subacute PSA patients, yet these individuals were not suffering from NFA (83-87). The Naeser team reported improvements in Phrase Length and picture naming on the BNT following the suppression of the posterior R IFG pr through the application of LF-rTMS in NFA patients. Nevertheless, the exclusion was due to the absence of control groups not comprised of stroke patients, rendering it impossible to extract and cross-reference assessment data (88-93).

The present study aimed to provide an updated overview of the current evidence about the efficacy of rTMS in treating NFA. Firstly, this review found that rTMS could improve NFA in stroke patients, evidenced by increased aphasia quotient (AQ) scores in the rTMS group. AQ is an indicator of aphasia severity and serves as a metric for assessing aphasia improvement (94). Subgroup analysis revealed that rTMS significantly enhanced repetition and naming abilities in stroke patients at various stages. Additionally, spontaneous language





improvement was noted in both acute and recovery phase patients, although the effects in the sequelae stage require further investigation. In our pursuit to examine studies focusing on the impact of rTMS on language skills, we discovered that several of these studies provided valuable insights beyond our initial scope. Interestingly, this exploration led us to understand that depression alleviation and the increase of BDNF may also benefit from rTMS. Admittedly, these findings are only based on 2 studies (each), and further research is necessary.

Stroke damages brain regions responsible for language expression and auditory comprehension, leading to aphasia, which in turn worsens functional outcomes (95). Aphasia improvement is linked to the rebalancing of activity between the perilesional ipsilateral and contralateral hemispheres, making rTMS a promising method for promoting language recovery (5, 96). The meta-analysis primarily focused on single-site and LF-rTMS stimulation, uncovering a notable association between the activation level of the IFG-R and patients' fluency (97). Lefaucheur et al. (16) proposed Level B evidence supporting the utilization of LF-rTMS on the IFG-R in patients suffering from NFA, especially when combined with SLT. Both HF-rTMS and LF-rTMS applied to one hemisphere, have demonstrated effectiveness in treating NFA (13). HF-rTMS enhances cerebral cortex excitability and revives bilateral cerebral hemisphere function by stimulating local neurons in the language center (98). However, HF-rTMS can cause intracranial hemorrhage and epilepsy, leading to its limited use in clinical and research settings. In one study (67), bilateral hemispheric stimulation (LF-rTMS applied to the right unaffected Broca's area and HF-rTMS targeting the left affected Broca's area) led to significant language function improvements, including repetition, naming, word comprehension, and fluency. These improvements were observed immediately after treatment and lasted for 2 months. Similarly, Vuksanović et al. (99) observed that the integration of cTBS applied to the right hemisphere with iTBS targeting the left, followed by 45 min of SLT, improved various language functions.

Aphasia, a neural network disorder, involves changes in the brain's functional connections. The reinstatement of the language network structure and function is crucial for restoring language abilities in individuals with aphasia (100). Regional homogeneity (Reho) analysis revealed that in aphasia patients, the activation of the IFG-L and left cuneiform lobe was lower compared to normal subjects, and there was a reduction in the functional connection between the left medial temporal gyrus (MTG-L) and superior temporal gyrus (STG-L) (101). rTMS has been demonstrated to enhance the functional connections between the bilateral frontal lobes and the left temporal lobe (35). Lin et al. (69) investigated the relationship between functional connectivity in language-related regions and language performance. The LF-rTMS group demonstrated significant functional connectivity remodeling, which fostered positive changes in brain plasticity. This aligns with the theory of improving the "Inter-hemispheric competition pattern" (102). Therefore, imaging analysis holds a crucial role in comprehensively assessing disruption and remodeling of the language network following a stroke.

Regarding the risk of bias, Egger's test results indicated that publication bias was not significant in the language domains such as repetition and overall language proficiency (p > 0.1). However, there was a significant presence of bias in naming and spontaneous speech categories (p < 0.1). Of the seven domains assessed by RevMan 5.4, the domain of random sequence generation exhibited the highest risk of bias.

The review also indicated that rTMS can enhance linguistic functions by increasing serum BDNF levels. BDNF, the most abundant neurotrophin in the cerebrum and predominantly found in the forebrain, is closely associated with cognitive and language functions. It plays a crucial role in facilitating the neuroplasticity process in PSA patients (65). LF-rTMS (43) and iTBS (65) have been shown to elevate BDNF levels in the peripheral serum of the rTMS group, reflecting changes in brain BDNF concentration. Poststroke depression (PSD) affects 30–60% of stroke survivors (103), which also relates to the language performance of stroke patients (10). Recognized as an effective treatment for depression, rTMS is supported by level A evidence (16). The meta-analysis demonstrated that both LF-rTMS and HF-rTMS significantly reduced depression scores and improved mood in the meta-analysis. Our findings indicate that lower HAMD scores correlate with better linguistic function performance. In conclusion, notable improvements in mood or serum BDNF from rTMS in NFA patients positively influence linguistic functions.

Limitations and future directions

Recognition of numerous constraints is essential in this systematic review. Firstly, the high proportion of Chinese literature may cause some publication bias. Secondly, clinical and methodological heterogeneity among the included literature may influence overall results, including the age of patients and varied rTMS treatment regimens. Thirdly, owing to restrictions on article length, only some meta-analysis findings were reported. In the future, we can discuss the therapeutic effects of different dosages of rTMS and different rTMS approaches, and design accurate rTMS parameters according to aphasia types, combined with functional imaging technology to further explore the related mechanisms.

Conclusion

Collectively, the reviewed literature provides compelling support for the utilization of rTMS as a viable non-pharmacological intervention aiding in the recovery of non-fluent aphasia post-stroke, including the ability of repetition, naming, and spontaneous language which may be accompanied by the improvement of serum BDNF and alleviation in depression in patients.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

References

1. Greco A, Occhipinti G, Giacoppo D, Agnello F, Laudani C, Spagnolo M, et al. Antithrombotic therapy for primary and secondary prevention of ischemic stroke: JACC state-of-the-art review. *J Am Coll Cardiol.* (2023) 82:1538–57. doi: 10.1016/j. jacc.2023.07.025

2. Zhang Y, He X, Hu S, Hu S, He F, Shen Y, et al. Efficacy and safety of massage in the treatment of post-stroke insomnia: a protocol for systematic review and meta-analysis. *Medicine*. (2020) 99:e23598. doi: 10.1097/MD.00000000023598

3. Vitti E, Hillis AE. Treatment of post-stroke aphasia: a narrative review for stroke neurologists. *Int J Stroke*. (2021) 16:1002–8. doi: 10.1177/17474930211017807

4. Low TA, Lindland K, Kirton A, Carlson HL, Harris AD, Goodyear BG, et al. Repetitive transcranial magnetic stimulation (RTMS) combined with multi-modality aphasia therapy for chronic post-stroke non-fluent aphasia: a pilot randomized sham-controlled trial. *Brain Lang.* (2023) 236:105216. doi: 10.1016/j.bandl.2022.105216

5. Crosson B, Rodriguez AD, Copland D, Fridriksson J, Krishnamurthy LC, Meinzer M, et al. Neuroplasticity and aphasia treatments: new approaches for an old problem. *J Neurol Neurosurg Psychiatry*. (2019) 90:1147–55. doi: 10.1136/jnnp-2018-319649

6. Georgiou AM, Kambanaros M. The effectiveness of transcranial magnetic stimulation (TMS) paradigms as treatment options for recovery of language deficits in chronic Poststroke aphasia. *Behav Neurol.* (2022) 2022:1–25. doi: 10.1155/2022/7274115

Author contributions

JC: Writing – original draft. YJ: Methodology, Writing – review & editing, Formal analysis. TR: Data curation, Writing – review & editing, Software. YY: Supervision, Writing – review & editing. YL: Supervision, Writing – review & editing. YZ: Writing – review & editing. SY: Writing – review & editing, Funding acquisition, Visualization.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (Grant no. 82074513) and the Natural Science Foundation of Fujian Province of China (Grant no. 2021J01955).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2024.1348695/ full#supplementary-material

7. Poslawsky IE, Schuurmans MJ, Lindeman E, Hafsteinsdóttir TB. A systematic review of nursing rehabilitation of stroke patients with aphasia. *J Clin Nurs.* (2010) 19:17–32. doi: 10.1111/j.1365-2702.2009.03023.x

8. Sinanović O, Mrkonjić Z, Zukić S, Vidović M, Imamović K. Post-stroke language disorders. Acta Clin Croat. (2011) 50:79–94.

9. Bonilha L, Hillis AE, Wilmskoetter J, Hickok G, Basilakos A, Munsell B, et al. Neural structures supporting spontaneous and assisted (entrained) speech fluency. *Brain.* (2019) 142:3951–62. doi: 10.1093/brain/awz309

10. Sheppard SM, Sebastian R. Diagnosing and managing post-stroke aphasia. *Expert Rev Neurother*. (2021) 21:221–34. doi: 10.1080/14737175.2020.1855976

11. Haro-Martínez A, Pérez-Araujo CM, Sanchez-Caro JM, Fuentes B, Díez-Tejedor E. Melodic intonation therapy for post-stroke non-fluent aphasia: systematic review and Meta-analysis. *Front Neurol.* (2021) 12:700115. doi: 10.3389/fneur.2021.700115

12. Marchina S, Norton A, Schlaug G. Effects of melodic intonation therapy in patients with chronic nonfluent aphasia. *Ann N Y Acad Sci.* (2023) 1519:173–85. doi: 10.1111/ nyas.14927

13. Starosta M, Cichoń N, Saluk-Bijak J, Miller E. Benefits from repetitive transcranial magnetic stimulation in post-stroke rehabilitation. *J Clin Med.* (2022) 11:2149. doi: 10.3390/jcm11082149

14. Hara T, Shanmugalingam A, McIntyre A, Burhan AM. The effect of non-invasive brain stimulation (nibs) on attention and memory function in stroke rehabilitation patients: a systematic review and Meta-analysis. *Diagnostics*. (2021) 11:227. doi: 10.3390/ diagnostics11020227

15. Kesikburun S. Non-invasive brain stimulation in rehabilitation. *Turk J Phys Med Rehabil.* (2022) 68:1–8. doi: 10.5606/tftrd.2022.10608

16. Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, di Lazzaro V, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (RTMS): an update (2014-2018). *Clin Neurophysiol.* (2020) 131:474–528. doi: 10.1016/j.clinph.2019.11.002

17. Martin PI, Naeser MA, Theoret H, Tormos JM, Nicholas M, Kurland J, et al. Transcranial magnetic stimulation as a complementary treatment for aphasia. *Semin Speech Lang*, (2004) 25:181–91. doi: 10.1055/s-2004-825654

18. Chou TY, Wang JC, Lin MY, Tsai PY. Low-frequency vs. Theta burst transcranial magnetic stimulation for the treatment of chronic non-fluent aphasia in stroke: a proof-of-concept study. *Front Aging Neurosci.* (2022) 13:800377. doi: 10.3389/fnagi.2021.800377

19. Fahmy EM, Elshebawy HM. Effect of high frequency transcranial magnetic stimulation on recovery of chronic post-stroke aphasia. *J Stroke Cerebrovasc Dis.* (2021) 30:105855. doi: 10.1016/j.jstrokecerebrovasdis.2021.105855

20. Georgiou A, Konstantinou N, Phinikettos I, Kambanaros M. Neuronavigated theta burst stimulation for chronic aphasia: two exploratory case studies. *Clin Linguist Phon.* (2019) 33:532–46. doi: 10.1080/02699206.2018.1562496

21. Ren C, Zhang G, Xu X, Hao J, Fang H, Chen P, et al. The effect of RTMS over the different targets on language recovery in stroke patients with global aphasia: a randomized sham-controlled study. *Biomed Res Int.* (2019) 2019:1–7. doi: 10.1155/2019/4589056

22. Hu XY, Zhang T, Rajah GB, Stone C, Liu LX, He JJ, et al. Effects of different frequencies of repetitive transcranial magnetic stimulation in stroke patients with non-fluent aphasia: a randomized, sham-controlled study. *Neurol Res.* (2018) 40:459–65. doi: 10.1080/01616412.2018.1453980

23. Haghighi M, Mazdeh M, Ranjbar N, Seifrabie MA. Further evidence of the positive influence of repetitive transcranial magnetic stimulation on speech and language in patients with aphasia after stroke: results from a double-blind intervention with sham condition. *Neuropsychobiology*. (2017) 75:185–92. doi: 10.1159/000486144

24. Hebert D, Lindsay MP, McIntyre A, Kirton A, Rumney PG, Bagg S, et al. Canadian stroke best practice recommendations: stroke rehabilitation practice guidelines, update 2015. *Int J Stroke*. (2016) 11:459–84. doi: 10.1177/1747493016643553

25. Zhang J, Zhong D, Xiao X, Yuan L, Li Y, Zheng Y, et al. Effects of repetitive transcranial magnetic stimulation (rtms) on aphasia in stroke patients: a systematic review and meta-analysis. *Clin Rehabil.* (2021) 35:1103–16. doi: 10.1177/0269215521999554

26. Arheix-Parras S, Barrios C, Python G, Cogné M, Sibon I, Engelhardt M, et al. A systematic review of repetitive transcranial magnetic stimulation in aphasia rehabilitation: leads for future studies. *Neurosci Biobehav Rev.* (2021) 127:212–41. doi: 10.1016/j.neubiorev.2021.04.008

27. Gholami M, Pourbaghi N, Taghvatalab S. Evaluation of rtms in patients with poststroke aphasia: a systematic review and focused meta-analysis. *Neurol Sci.* (2022) 43:4685–94. doi: 10.1007/s10072-022-06092-x

28. Kielar A, Patterson D, Chou YH. Efficacy of repetitive transcranial magnetic stimulation in treating stroke aphasia: systematic review and meta-analysis. *Clin Neurophysiol.* (2022) 140:196–227. doi: 10.1016/j.clinph.2022.04.017

29. Li T, Zeng X, Lin L, Xian T, Chen Z. Effects of repetitive transcranial magnetic stimulation with different frequencies on post-stroke aphasia: a Prisma-compliant meta-analysis. *Medicine*. (2020) 99:e20439. doi: 10.1097/MD.00000000020439

30. Wang C, Nie P, Wang P, Wang Y, Zang Y, Zhang Y. The therapeutic effect of transcranial magnetic stimulation on post-stroke aphasia and the optimal treatment parameters: a meta-analysis. *Arch Phys Med Rehabil.* (2023). doi: 10.1016/j.apmr. 2023.11.006

31. Georgiou AM, Lada E, Kambanaros M. Evaluating the quality of conduct of systematic reviews on the application of transcranial magnetic stimulation (TMS) for post-stroke aphasia rehabilitation. *Aphasiology.* (2019) 34:540–56. doi: 10.1080/02687038.2019.1632786

32. Zheng Y, Liu J, Wang Y, Xing J, Gu Y, Tang J. Low-frequency repetitive transcranial magnetic stimulation for non-fluent aphasia after stroke: a systematic review. *Chin J Rehabil.* (2021) 36:365–71.

33. Page MJ, McKenzie J, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The Prisma 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. (2021) 372:n71. doi: 10.1136/bmj.n71

34. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. (2019) 366:l4898. doi: 10.1136/bmj.l4898

35. Bai G, Jiang L, Sun D, Meng P, Yang CH, Zhang Z, et al. Based on the regional homogeneity method to explore the effect and mechanism of low-frequency repetitive transcranial magnetic stimulation on the auditory comprehension function of post-stroke patients with non-fluent aphasia. *Chin J Rehabil Med.* (2023) 38:606–12. doi: 10.3969/j.issn.1001-1242.2023.05.004

36. Cao H, Zhang W, Xu T, Cui X. Effect of eye tracking training combined with repetitive transcranial magnetic stimulation on post-stroke complete aphasia. *Chin J Rehabil.* (2023) 38:552–5. doi: 10.3870/zgkf.2023.09.009

37. Chang L. Clinical observation of low frequency repetitive transcranial magnetic stimulation on motor aphasia after acute cerebral infarction. *Neural Injury Funct Reconstr.* (2018) 13:53–4. doi: 10.16780/j.cnki.sjssgncj.2018.01.020

38. Shen Y, Yin Z, Zhou Q, Cong F, Yi W, Shan CH. Low frequency, repetitive transcranial magnetic stimulation can alleviate non-fluent aphasia after stroke. *Chin J Phys Med Rehabil.* (2016) 3:170–4. doi: 10.3760/cma.j.issn.0254-1424.2016.03.003

39. Chen Y, Gao H, Wang X, Zhou Y, Ou X, Pan C. Effect of low-frequency RTMS on rehabilitation of language and communication ability in patients with non-fluent aphasia after stroke. *Chin J Gerontol.* (2020) 40:709–12. doi: 10.3969/j.issn.1005-9202.2020.04.011

40. Shan Y, Wang L, Wang J, Luo Z, Zeng X. The effect of low frequency transcranial magnetic stimulation on aphasia after cerebral infarction. *Chin J Phys Med Rehabil.* (2012) 5:361–4. doi: 10.3760/cma.j.issn.0254-1424.2012.05.01

41. Fan Y, Zhao J. Therapeutic effect of low-frequency repetitive transcranial magnetic stimulation on motor aphasia after acute cerebral infarction. *Chin J Rehabil.* (2016) 31:28–30. doi: 10.3870/zgkf.2016.01.008

42. Guo C, Zhu G, Deng W, Ma T, Du A, Zhao Z. Effect of repetitive transcranial magnetic stimulation combined with memantine hydrochloride and speech therapy on the treatment of motor aphasia after cerebral infarction. *China Med Herald.* (2016) 13:83–6.

43. Jiang X, Liu Z, Su Q, Zhao Q, Xia X, Lu F. Effect of intermittent theta burst transcranial magnetic stimulation on non-fluent aphasia after stroke. *Chin J Rehabil Theory Pract.* (2023) 29:839–43. doi: 10.3969/j.issn.1006.9771.2023.07.014

44. Li W, Qin H, Wei X, Zhao P. Clinical observation on the treatment of post-stroke motor aphasia with consciousness-restoring resuscitation acupuncture combined with transcranial magnetic stimulation. *J Pract Trad Chin Med.* (2021) 37:858–60.

45. Li Z, Zhao Y, Ren C, Cai D, Wu SH, Fang H. Mechanism in the treatment of subacute motor aphasia with low frequency repetitive transcranial magnetic stimulation by quantitative electroencephalography. *Chin J Rehabil Med.* (2018) 33:794–9. doi: 10.3969/j.issn.1001-1242.2018.07.008

46. Liu S, Lv M, Wang Y, Liang J, Li T. Contralateral inhibitory repetitive transcranial magnetic stimulation combined with donepezil in the treatment of post-stroke non-fluent aphasia. *J Audiol Speech Pathol.* (2023) 31:165–9. doi: 10.3969/j.issn.1006-7299. 2023.02.016

47. Liu S, Hu X. Clinical observation of acupuncture combined with repetitive transcranial magnetic stimulation in the treatment of motor aphasia after stroke. *Clin J Trad Chin Med.* (2022) 34:2146–50. doi: 10.16448/j.cjtcm.2022.1135

48. Pan L, Ma J, Peng Y, Sun J, Zhu B. Electro-acupuncture combined with high frequency repetitive transcranial magnetic stimulation in the treatment of motor aphasia after stroke. *China J Chin Med.* (2019) 34:1985–9. doi: 10.16368/j.issn.1674-8999.2019.09.463

49. Qiao Y, Ma J, Peng Y, Sun J, Zhu B. Clinical study of electro-acupuncture combined with Low- frequency rtms on motor aphasia after stroke. *J Clin Acupunct Moxibust.* (2019) 35:15–9. doi: 10.3969/j.issn.1005-0779.2019.10.005

50. Qin Q. Efficacy of low-frequency repetitive transcranial magnetic stimulation combined with hyperbaric medicine aphasia after stroke. *Med Diet Health.* (2020) 18:53–4.

51. Qiu L, Cai Y, Jiang Y, Lin W, Li X. Effects of response elaboration training combined with RTMS in patients with non-fluent aphasia. *Chin J Rehabil Med.* (2020) 35:1192–7. doi: 10.3969/j.issn.1001-1242.2020.10.007

52. Qu Y, Zhong G, Lv J, et al. Observation on the efficacy of low frequency repetitive transcranial magnetic stimulation in the treatment of non-fluent aphasia after subacute stroke. *China Modern Doctor*. (2020) 58:112–5.

53. Ren C, Cai D, Fang H, Chen P, Li ZH, Wu SH. Effects of low frequency rtms over the right superior temporal gyrus on language function in subacute global poststroke aphasia patients. *J Rehabil Med.* (2018) 33:1055–9. doi: 10.3969/j. issn.1001-1242.2018.09.009

54. Wang G, Liu M, Sheng Y, He SH, Xie J, Long J. Clinical study of RTMS combined with speech training in the treatment of aphasia after stroke. *Shenzhen J Integr Trad Chin Western Med.* (2021) 31:1–4. doi: 10.16458/j.cnki.1007-0893.2021.06.001

55. Wang J, Li J, Zhang Y, Bai G, Han CH, Yang CH, et al. Effect of low frequency repetitive transcranial magnetic stimulation on non-fluent aphasia after stroke. *Chin J Rehabil Med.* (2018) 33:1463–4. doi: 10.3969/j.issn.1001-1242.2018.12.018

56. Wu G, Yang H, Pan L. Effect and mechanism of repetitive transcranial magnetic stimulation on aphasia in patients with left hemisphere cerebral infarction. *Shandong Med J.* (2017) 57:65–7. doi: 10.3969/j.issn.1002-266X.2017.37.022

57. Xu D, Liu H. Effect of repetitive transcranial magnetic stimulation combined with speech training on motor aphasia after stroke. *Med Innov China*. (2022) 19:147–50. doi: 10.3969/j.issn.1674-4985.2022.02.037

58. Zhang D, Wang J, Lu J, Wang P, Cheng Y, Yuan Y, et al. Efficacy comparison of noninvasive brain stimulation techniques on picture naming ability of non fluent aphasia patients after stroke with normal expression capacity. *Chin J Cerebrovasc Dis.* (2021) 18:84–90. doi: 10.3969/j.issn.1672-5921.2021.02.002

59. Zhang Y, Yun W, Zhang M, Chen Y, Cao Y, Zhou X. The effects of low-frequency repetitive transcranial magnetic stimulation combined with hyperbaric oxygen in the

treatment of non-fluent aphasia. Chin J Phys Med Rehabil. (2019) 7:512–6. doi: 10.3760/ cma.j.issn.0254-1424.2019.07.008

60. Zheng Y, Gu Y, Yuan L, Zhang W, Shi CH, Tang J. Attention should be paid to the effect of training combined with repetitive transcranial magnetic stimulation in the treatment of non-fluent aphasia after stroke. *J Audiol Speech Pathol.* (2022) 30:304–7. doi: 10.3969/j.issn.1006-7229.2022.03.015

61. Zhou H, Yuan L, Wen Y, Jiang W, Yang L, Chen H, et al. Effect of low-frequency repetitive transcranial magnetic stimulation combined with speech training on the rehabilitation of stroke aphasia. *Neural Inj Funct Reconstr.* (2021) 16:614–6. doi: 10.16780/j.cnki.sjssgncj.20201268

62. Zhu H, Cheng X, Liu L, Tian L, Rao J, Liu Y, et al. Clinical observation of inhibitory repetitive transcranial magnetic stimulation in stroke patients with non-fluent aphasia. *Zhejiang Med J.* (2023) 45:1140–1145+1151. doi: 10.12056/j. issn.1006-2785.2023.45.11.2022-232

63. Zhu H, Zhang X, Cheng X, Rao J, Zhang Y, Liu L. Effect of inhibitory repetitive transcranial magnetic stimulation combined with mirror neuron training system for stroke patients with global aphasia. *Chin J Rehabil.* (2020) 35:563–7. doi: 10.3870/ zgkf.2020.22.001

64. Zhu H, Zhang X, Cheng X, Rao J, Zhang Y, Liu L. The effect of inhibitory repetitive transcranial magnetic stimulation combined with Mirror neuron training system on chronic global aphasia Poststroke. *Chin J Stroke*. (2021) 16:45–50. doi: 10.3969/j. issn.1673-5765.2021.01.008

65. Bai G, Jiang L, Huan S, Meng P, Wang Y, Pan X, et al. Study on Low-frequency repetitive transcranial magnetic stimulation improves speech function and mechanism in patients with non-fluent aphasia after stroke. *Front Aging Neurosci.* (2022) 14:883542. doi: 10.3389/fnagi.2022.883542

66. Barwood CH, Murdoch BE, Riek S, O'Sullivan JD, Wong A, Lloyd D, et al. Long term language recovery subsequent to low frequency rtms in chronic non-fluent aphasia. *NeuroRehabilitation*. (2013) 32:915–28. doi: 10.3233/NRE-130915

67. Khedr EM, Abo el-Fetoh N, Ali AM, el-Hammady DH, Khalifa H, Atta H, et al. Dual-hemisphere repetitive transcranial magnetic stimulation for rehabilitation of poststroke aphasia: a randomized, double-blind clinical trial. *Neurorehabil Neural Repair.* (2014) 28:740–50. doi: 10.1177/1545968314521009

68. Lin BF, Hon F, Lin MY, Tsai PY, Lu CF. Right arcuate fasciculus as outcome predictor after low-frequency repetitive transcranial magnetic stimulation in nonfluent aphasic stroke. *Eur J Neurol.* (2023) 30:2031–41. doi: 10.1111/ene.15808

69. Lin BF, Yeh SC, Kao YJ, Lu CF, Tsai PY. Functional remodeling associated with language recovery after repetitive transcranial magnetic stimulation in chronic aphasic stroke. *Front Neurol.* (2022) 13:809843. doi: 10.3389/fneur.2022.809843

70. Lopez-Romero LA, Riano-Carreno DM, Pachon-Poveda MY, Mendoza-Sanchez JA, Leon-Vargas YK, Moreno-Pabon A, et al. Efficacy and safety of transcranial magnetic stimulation in patients with non-fluent aphasia, following an ischaemic stroke. A controlled, randomised and double-blind clinical trial. *Rev Neurol.* (2019) 68:241–9. doi: 10.33588/rn.6806.2018300

71. Medina J, Norise C, Faseyitan O, Coslett HB, Turkeltaub PE, Hamilton RH. Finding the right words: transcranial magnetic stimulation improves discourse productivity in non-fluent aphasia after stroke. *Aphasiology*. (2012) 26:1153–68. doi: 10.1080/02687038.2012.710316

72. Tsai PY, Wang CP, Ko JS, Chung YM, Chang YW, Wang JX. The persistent and broadly modulating effect of inhibitory rtms in nonfluent aphasic patients: a sham-controlled, double-blind study. *Neurorehabil Neural Repair.* (2014) 28:779–87. doi: 10.1177/1545968314522710

73. Wang CP, Hsieh CY, Tsai PY, Wang CT, Lin FG, Chan RC. Efficacy of synchronous verbal training during repetitive transcranial magnetic stimulation in patients with chronic aphasia. *Stroke.* (2014) 45:3656–62. doi: 10.1161/STROKEAHA.114.007058

74. YAŞA İC, MAVİŞ İ, ŞALÇİNİ C, MİDİ İ. Comparing the efficiency of speech and language therapy and transcranial magnetic stimulation for treating Broca's aphasia. J Stroke Cerebrovasc Dis. (2023) 32:107108. doi: 10.1016/j.jstrokecerebrovasdis.2023.107108

75. Yoon TH, Han SJ, Yoon TS, Kim JS, Yi TI. Therapeutic effect of repetitive magnetic stimulation combined with speech and language therapy in post-stroke non-fluent aphasia. *NeuroRehabilitation*. (2015) 36:107–14. doi: 10.3233/NRE-141198

76. Yu EH, Min JH, Shin YI, Ko HY, Ko SH. Effect of repetitive transcranial magnetic stimulation on post-stroke non-fluent aphasia in relation with Broca's area. *Brain Neurorehabil.* (2021) 14:e15. doi: 10.12786/bn.2021.14.e15

77. Zheng K, Chen M, Shen Y, Xu X, Gao F, Huang G, et al. Cerebellar continuous Theta burst stimulation for aphasia rehabilitation: study protocol for a randomized controlled trial. *Front Aging Neurosci.* (2022) 14:909733. doi: 10.3389/fnagi.2022.909733

78. Chen F, Wang X, Zhan C, Yang L, Wang Y, Sun x, et al. Therapeutical effect of low-frequency repetitive transcranial magnetic stimulation on cerebral infarction aphasia and its possible mechanism. *Chin J Cerebrovasc Dis.* (2012) 6:246–51. doi: 10.3877/cma.j.issn.1673-9248.2012.05.002

79. Chen F, Wang X, Sun X, Ke SH, Wang Y, Zhao X, et al. Therapeutical effect of low-frequency repetitive transcranial magnetic stimulation on cerebral infarction aphasia and its effect on brain electrical activity. *Chin J Cerebrovasc Dis.* (2011) 5:96–101. doi: 10.3969/j.issn.1672-9248.2011.02.003

80. Barwood CH, Murdoch BE, Whelan BM, Lloyd D, Riek S, O' Sullivan JD, et al. Improved language performance subsequent to low-frequency rtms in patients with chronic non-fluent aphasia post-stroke. *Eur J Neurol.* (2011) 18:935–43. doi: 10.1111/j.1468-1331.2010.03284.x

81. Sang B, Deng S, Zhai J, Hao T, Zhuo B, Qin C, et al. Does acupuncture therapy improve language function of patients with aphasia following ischemic stroke? A systematic review and meta-analysis. *NeuroRehabilitation*. (2022) 51:231–45. doi: 10.3233/NRE-220007

82. Harvey DY, Podell J, Turkeltaub PE, Faseyitan O, Coslett HB, Hamilton RH. Functional reorganization of right prefrontal cortex underlies sustained naming improvements in chronic aphasia via repetitive transcranial magnetic stimulation. *Cogn Behav Neurol.* (2017) 30:133–44. doi: 10.1097/WNN.00000000000141

83. Zumbansen A, Black SE, Chen JL, J Edwards D, Hartmann A, Heiss WD, et al. Non-invasive brain stimulation as add-on therapy for subacute post-stroke aphasia: a randomized trial (Northstar). *Eur Stroke J.* (2020) 5:402–13. doi: 10.1177/2396987320934935

84. Thiel A, Black SE, Rochon EA, Lanthier S, Hartmann A, Chen JL, et al. Noninvasive repeated therapeutic stimulation for aphasia recovery: a multilingual, multicenter aphasia trial. *J Stroke Cerebrovasc Dis.* (2015) 24:751–8. doi: 10.1016/j. jstrokecerebrovasdis.2014.10.021

85. Rubi-Fessen I, Hartmann A, Huber W, Fimm B, Rommel T, Thiel A, et al. Add-on effects of repetitive transcranial magnetic stimulation on subacute aphasia therapy: enhanced improvement of functional communication and basic linguistic skills. A randomized controlled study. *Arch Phys Med Rehabil.* (2015) 96:1935–1944.e2. doi: 10.1016/j.apmr.2015.06.017

86. Winhuisen L, Thiel A, Schumacher B, Kessler J, Rudolf J, Haupt WF, et al. Role of the contralateral inferior frontal gyrus in recovery of language function in poststroke aphasia: a combined repetitive transcranial magnetic stimulation and positron emission tomography study. *Stroke.* (2005) 36:1759–63. doi: 10.1161/01.STR.0000174487. 81126.ef

87. Weiduschat N, Thiel A, Rubi-Fessen I, Hartmann A, Kessler J, Merl P, et al. Effects of repetitive transcranial magnetic stimulation in aphasic stroke: a randomized controlled pilot study. *Stroke*. (2011) 42:409–15. doi: 10.1161/STROKEAHA.110.597864

88. Martin PI, Treglia E, Naeser MA, Ho MD, Baker EH, Martin EG, et al. Language improvements after TMS plus modified CILT: pilot, open-protocol study with two, chronic nonfluent aphasia cases. *Restor Neurol Neurosci.* (2014) 32:483–505. doi: 10.3233/RNN-130365

89. Garcia G, Norise C, Faseyitan O, Naeser MA, Hamilton RH. Utilizing repetitive transcranial magnetic stimulation to improve language function in stroke patients with chronic non-fluent aphasia. *J Vis Exp.* (2013) 77:e50228. doi: 10.3791/50228-v

90. Naeser MA, Martin PI, Theoret H, Kobayashi M, Fregni F, Nicholas M, et al. Tms suppression of right pars triangularis, but not pars opercularis, improves naming in aphasia. *Brain Lang.* (2011) 119:206–13. doi: 10.1016/j.bandl.2011.07.005

91. Naeser MA, Martin PI, Lundgren K, Klein R, Kaplan J, Treglia E, et al. Improved language in a chronic nonfluent aphasia patient after treatment with CPAP and TMS. *Cogn Behav Neurol.* (2010) 23:29–38. doi: 10.1097/WNN.0b013e3181bf2d20

92. Hamilton RH, Sanders L, Benson J, Faseyitan O, Norise C, Naeser M, et al. Stimulating conversation: enhancement of elicited propositional speech in a patient with chronic non-fluent aphasia following transcranial magnetic stimulation. *Brain Lang.* (2010) 113:45–50. doi: 10.1016/j.bandl.2010.01.001

93. Naeser MA, Martin PI, Nicholas M, Baker EH, Seekins H, Helm-Estabrooks N, et al. Improved naming after TMS treatments in a chronic, global aphasia patient – case report. *Neurocase*. (2005) 11:182–93. doi: 10.1080/13554790590944663

94. Ding X, Zhang S, Huang W, Zhang S, Zhang L, Hu J, et al. Comparative efficacy of non-invasive brain stimulation for post-stroke aphasia: a network meta-analysis and meta-regression of moderators. *Neurosci Biobehav Rev.* (2022) 140:104804. doi: 10.1016/j.neubiorev.2022.104804

95. Grönberg A, Henriksson I, Stenman M, Lindgren AG. Incidence of aphasia in ischemic stroke. *Neuroepidemiology*. (2022) 56:174–82. doi: 10.1159/000524206

96. Bucur M, Papagno C. Are transcranial brain stimulation effects long-lasting in post-stroke aphasia? A comparative systematic review and meta-analysis on naming performance. *Neurosci Biobehav Rev.* (2019) 102:264–89. doi: 10.1016/j.neubiorev. 2019.04.019

97. Johnson L, Yourganov G, Basilakos A, Newman-Norlund RD, Thors H, Keator L, et al. Functional connectivity and speech entrainment speech entrainment improves connectivity between anterior and posterior cortical speech areas in non-fluent aphasia. *Neurorehabil Neural Repair.* (2022) 36:164–74. doi: 10.1177/15459683211064264

98. Chang WK, Park J, Lee JY, Cho S, Lee J, Kim WS, et al. Functional network changes after high-frequency RTMS over the Most activated speech-related area combined with speech therapy in chronic stroke with non-fluent aphasia. *Front Neurol.* (2022) 13:690048. doi: 10.3389/fneur.2022.690048

99. Vuksanović J, Jelić MB, Milanović SD, Kačar K, Konstantinović L, Filipović SR. Improvement of language functions in a chronic non-fluent post-stroke aphasic patient following bilateral sequential theta burst magnetic stimulation. *Neurocase*. (2015) 21:244–50. doi: 10.1080/13554794.2014.890731 100. Iorga M, Higgins J, Caplan D, Zinbarg R, Kiran S, Thompson CK, et al. Predicting language recovery in post-stroke aphasia using behavior and functional MRI. *Sci Rep.* (2021) 11:8419. doi: 10.1038/s41598-021-88022-z

101. Li H, Zhang H, Xu S, Wang M, Zhang J, Liu J, et al. Altered spontaneous brain activity in Poststroke aphasia: a resting-state fmri study. *Brain Sci.* (2023) 13:300. doi: 10.3390/brainsci13020300

102. Carson RG. Inter-hemispheric inhibition sculpts the output of neural circuits by co-opting the two cerebral hemispheres. *J Physiol.* (2020) 598:4781–802. doi: 10.1113/JP279793

103. Cai W, Mueller C, Li YJ, Shen WD, Stewart R. Post stroke depression and risk of stroke recurrence and mortality: a systematic review and meta-analysis. *Ageing Res Rev.* (2019) 50:102–9. doi: 10.1016/j.arr.2019.01.013